Implantable lead affixation structure for nerve stimulation to alleviate bladder dysfunction and other indication

Description

FIELD OF THE INVENTION

The present invention relates to neurostimulation treatment systems and associated devices, as well as methods of treatment, implantation and configuration of such treatment systems.

BACKGROUND OF THE INVENTION

Treatments with implantable neurostimulation systems have become increasingly common in recent years. While such systems have shown promise in treating a number of conditions, effectiveness of treatment may vary considerably between patients. A number of factors may lead to the very different outcomes that patients experience, and viability of treatment can be difficult to determine before implantation. For example, stimulation systems often make use of an array of electrodes to treat one or more target nerve structures. The electrodes are often mounted together on a multi-electrode lead, and the lead implanted in tissue of the patient at a position that is intended to result in electrical coupling of the electrode to the target nerve structure, typically with at least a portion of the coupling being provided via intermediate tissues. Other approaches may also be employed, for example, with one or more electrodes attached to the skin overlying the target nerve structures, implanted in cuffs around a target nerve, or the like. Regardless, the physician will typically seek to establish an appropriate treatment protocol by varying the electrical stimulation that is applied to the electrodes.

Current stimulation electrode placement/implantation techniques and known treatment setting techniques suffer from significant disadvantages. The nerve tissue structures of different patients can be quite different, with the locations and branching of nerves that perform specific functions and/or enervate specific organs being challenging to accurately predict or identify. The electrical properties of the tissue structures surrounding a target nerve structure may also be quite different among different patients, and the neural response to stimulation may be markedly dissimilar, with an electrical stimulation pulse pattern, pulse width, frequency, and/or amplitude that is effective to affect a body function of one patient and potentially imposing significant discomfort or pain, or having limited effect, on another patient. Even in patients where implantation of a neurostimulation system provides effective treatment, frequent adjustments and changes to the stimulation protocol are often required before a suitable treatment program can be determined, often involving repeated office visits and significant discomfort for the patient before efficacy is achieved. While a number of complex and sophisticated lead structures and stimulation setting protocols have been implemented to seek to overcome these challenges, the variability in lead placement results, the clinician time to establish suitable stimulation signals, and the discomfort (and in cases the significant pain) that is imposed on the patient remain less than ideal. In addition, the lifetime and battery life of such devices is relatively short, such that implanted systems are routinely replaced every few years, which requires additional surgeries, patient discomfort, and significant costs to healthcare systems.

Furthermore, since the morphology of the nerve structures vary considerably between patients, placement and alignment of neurostimulation leads relative the targeted nerve structures can be difficult to control, which can lead to inconsistent placement, unpredictable results and widely varying patient outcomes. For these reasons, neurostimulation leads typically include multiple electrodes with the hope that at least one electrode or a pair of electrodes will be disposed in a location suitable for delivering neurostimulation. One drawback with this approach is that repeated office visits may be required to determine the appropriate electrodes to use and/or to arrive at a neurostimulation program that delivers effective treatment. Often, the number of usable neurostimulation programs may be limited by imprecise lead placement.

The tremendous benefits of these neural stimulation therapies have not yet been fully realized. Therefore, it is desirable to provide improved neurostimulation methods, systems and devices, as well as methods for implanting such neurostimulation systems for a particular patient or condition being treated. It would be particularly helpful to provide such systems and methods so as to improve ease of use by the physician in positioning and affixation of such leads to ensure proper lead placement is maintained after implantation so as to provide consistent and predictable results upon delivery of neurostimulation therapy. Therefore, it is desirable to provide methods and devices for implanting neurostimulation leads that improve anchoring of the lead and allow for reduced delivery profile of the lead during implantation.

BRIEF SUMMARY OF THE INVENTION

The present invention relates to implantable neurostimulation systems, and in particular to devices and methods for anchoring implanted neurostimulation leads. In one aspect, the invention includes an anchoring body extending helically about the lead and a plurality of tines disposed along the anchoring body. The plurality of tines are biased toward a deployed position in which the tines extend laterally outward from the helical body so as to engage tissue sufficiently to inhibit axial displacement of the implanted lead. The tines are constructed so as to be resiliently deflectable toward the helical body during implantation so as to fold inward toward the helical anchoring body when constrained by a delivery sheath to facilitate delivery to the target location during implantation.

In one aspect, a neurostimulation system in accordance with aspect of the invention includes an implantable lead having one or more conductors disposed within a lead body, the one or more conductors extending from a proximal end of the lead to one or more neurostimulation electrodes disposed at or near a distal end of the lead; a pulse generator coupleable to the proximal end of the implantable lead, the pulse generator being electrically coupled with the one or more neurostimulation electrodes when coupled to the implantable lead, the pulse generator being configured to generate a plurality of electrical impulses for delivering a neurostimulation treatment to a patient through the one or more neurostimulation electrodes when implanted at a target location; and an anchor coupled with the lead body just proximal of the electrodes.

In one aspect, the anchor includes a helical body extending helically on the outside of the lead body along a longitudinal axis thereof and a plurality of tines extending laterally away from the helical body. Each of the plurality of tines is biased to a deployed configuration and a delivery configuration. In the deployed configuration, the plurality of tines extend laterally away from longitudinal axis when the helical body is disposed thereon, and in the delivery configuration, the plurality of tines are folded inward toward the longitudinal axis of the lead body to facilitate delivery of the neurostimulation lead during implantation. In certain embodiments, the anchor is configured such that, in the delivery configuration, each of the plurality of tines is folded against the lead body so as to further reduce the delivery profile and, in the delivery configuration, the anchor has a cross-section or crossing profile compatible with a sheath having a diameter of 5 French or higher. In certain embodiments, the helical body and the plurality of tines are integrally formed of the same material, while in other embodiments the tines may be separate elements attached to the helical body. The tines are formed of a material with sufficient stiffness so that engagement of tissue with the plurality of tines inhibits axial movement of the lead when implanted in a tissue of the patient at the target location. In some embodiments, the anchor may be molded from a polyurethane based material having a shore hardness within a range between 50A and 80D. In other embodiments, the anchor may be formed of a metal, such as a shape-memory alloy. In still other embodiments, the anchor may be formed of a combination of materials, such as a polymer based material and a metal, such as a shape-memory alloy wire.

In certain embodiments, the anchor is dimensioned so that the helical body extends a length between 10 mm to 30 mm along the lead body when coupled thereon, preferably about 20 mm. Each of the plurality of tines may extend laterally outward from the longitudinal axis a distance between 1 mm to 4 mm. Each of the plurality of tines may be between 1.5 mm to 3 mm in length and between 0.5 mm to 2.0 mm in width. In some embodiments, the plurality of tines include tines of varying length, width and angle in the proximal direction, while in other embodiments, the plurality of tines may be of differing lengths or may angle in both proximal and distal directions. The plurality of tines may have a generally rectangular tab shape and may include rounded or chamfered corners and/or edges so as to inhibit tissue damage at the corners and/or edges. In some embodiments, the tines are biased toward an angle between 30 to 80 degrees from the longitudinal axis in the deployed configuration.

In one aspect, the helical body attaches to the lead body in an anchoring portion having a recessed portion with a reduced profile so as to further reduce the cross section, such as to 2 mm or less so as to accommodate a 5 French sheath for use in implanting the lead. In some embodiments, the anchor includes multiple anchor sections that may be attached to one another and deployed adjacent one another. This feature may allow the user to customize the anchoring portion as to both length and tine direction of the anchor, by reverse the anchors or combining differing types of anchors within the anchoring portion. The anchor may further include one or more additional features, including any of: a radiopaque element extending a substantial length of the helical body so as to facilitate positioning using visualization techniques; an embedded shield material suitable for shielding magnetic resonance induced heating; and biodegradable or drug eluting tines.

In certain embodiments, the helical body is a continuous helical flap and the plurality of tines comprise a plurality of sections of the continuous helical flap, the plurality of section defined by a plurality of cuts along a length of the continuous helical flap so as to allow the plurality of sections to fold inward without overlapping one another.

In other embodiments, the anchor is formed by laser cutting a tubular portion of a material (e.g. polymer or metal, such as Nitinol) and setting the material while the anchor is in the deployed configuration by heat setting or reflow. In still other embodiments, the anchor may be formed by injection molding a polymer material in a multi-piece mold assembly, which allows for further variability in the anchor structure, such as varying thicknesses in different portions of the anchor.

Further areas of applicability of the present disclosure will become apparent from the detailed description provided hereinafter. It should be understood that the detailed description and specific examples, while indicating various embodiments, are intended for purposes of illustration only and are not intended to necessarily limit the scope of the disclosure.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 schematically illustrates a nerve stimulation system, which includes a clinician programmer and a patient remote used in positioning and/or programming of both a trial neurostimulation system and a permanently implanted neurostimulation system, in accordance with aspects of the invention.

FIGS. 2A-2C show diagrams of the nerve structures along the spine, the lower back and sacrum region, which may be stimulated in accordance with aspects of the invention.

FIG. 3A shows an example of a fully implanted neurostimulation system in accordance with aspects of the invention.

FIG. 3B shows an example of a neurostimulation system having a partly implanted stimulation lead and an external pulse generator adhered to the skin of the patient for use in a trial stimulation, in accordance with aspects of the invention.

FIG. 4 shows an example of a neurostimulation system having an implantable stimulation lead, an implantable pulse generator, and an external charging device, in accordance with aspects of the invention.

FIG. 5A-5C show detail views of an implantable pulse generator and associated components for use in a neurostimulation system, in accordance with aspects of the invention.

FIGS. 6A-6C show a strain relief structure for use with a neurostimulation lead and implantable pulse generator, in accordance with aspects of the invention.

FIG. 7 illustrates a neurostimulation lead with an anchor structure thereon, in accordance with aspects of the invention.

FIG. 8 illustrates an example anchor structure, in accordance with aspects of the invention.

FIGS. 9A-9B illustrate a neurostimulation lead with an anchor structure thereon before and after deployment, in accordance with aspects of the invention.

FIGS. 10A-10B illustrate an example anchor structure, in accordance with aspects of the invention.

FIGS. 11A-11B illustrate an example anchor structure, in accordance with aspects of the invention.

FIGS. 12A-12B illustrate an example anchor structure, in accordance with aspects of the invention.

FIGS. 13A-13B illustrate an example anchor structure, in accordance with aspects of the invention.

FIGS. 14A-14B illustrate an example anchor structure, in accordance with aspects of the invention.

FIGS. 15A-15C illustrate an example anchor structure before and after deployment and FIG. 15C illustrates an end view of the deployed anchor structure, in accordance with aspects of the invention.

FIGS. 16A-16B illustrate an example anchor structure formed by laser cutting, the structure shown before and after deployment, in accordance with aspects of the invention.

FIGS. 17A-17B illustrate an alternative illustrate an example anchor structure formed by an injection molding process, in accordance with aspects of the invention.

FIGS. 18-20 illustrate methods of forming an anchor and methods of anchoring a neurostimulation lead in accordance with aspects of the invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to neurostimulation treatment systems and associated devices, as well as methods of treatment, implantation/placement and configuration of such treatment systems. In particular embodiments, the invention relates to sacral nerve stimulation treatment systems configured to treat bladder dysfunctions, including overactive bladder (“OAB”), as well as fecal dysfunctions and relieve symptoms associated therewith. It will be appreciated however that the present invention may also be utilized for the treatment of pain or other indications, such as movement or affective disorders, as will be appreciated by one of skill in the art.

I. Neurostimulation Indications

Neurostimulation treatment systems, such as any of those described herein, can be used to treat a variety of ailments and associated symptoms, such as acute pain disorders, movement disorders, affective disorders, as well as bladder related dysfunction and bowel and fecal dysfunction. Examples of pain disorders that may be treated by neurostimulation include failed back surgery syndrome, reflex sympathetic dystrophy or complex regional pain syndrome, causalgia, arachnoiditis, and peripheral neuropathy. Movement orders include muscle paralysis, tremor, dystonia and Parkinson's disease. Affective disorders include depressions, obsessive-compulsive disorder, cluster headache, Tourette syndrome and certain types of chronic pain. Bladder related dysfunctions include but are not limited to OAB, urge incontinence, urgency-frequency, and urinary retention. OAB can include urge incontinence and urgency-frequency alone or in combination. Urge incontinence is the involuntary loss or urine associated with a sudden, strong desire to void (urgency). Urgency-frequency is the frequent, often uncontrollable urges to urinate (urgency) that often result in voiding in very small amounts (frequency). Urinary retention is the inability to empty the bladder. Neurostimulation treatments can be configured to address a particular condition by effecting neurostimulation of targeted nerve tissues relating to the sensory and/or motor control associated with that condition or associated symptom.

In one aspect, the methods and systems described herein are particularly suited for treatment of urinary and fecal dysfunctions. These conditions have been historically under-recognized and significantly underserved by the medical community. OAB is one of the most common urinary dysfunctions. It is a complex condition characterized by the presence of bothersome urinary symptoms, including urgency, frequency, nocturia and urge incontinence. It is estimated that about 40 million Americans suffer from OAB. Of the adult population, about 16% of all men and women live with OAB symptoms.

OAB symptoms can have a significant negative impact on the psychosocial functioning and the quality of life of patients. People with OAB often restrict activities and/or develop coping strategies. Furthermore, OAB imposes a significant financial burden on individuals, their families, and healthcare organizations. The prevalence of co-morbid conditions is also significantly higher for patients with OAB than in the general population. Co-morbidities may include falls and fractures, urinary tract infections, skin infections, vulvovaginitis, cardiovascular, and central nervous system pathologies. Chronic constipation, fecal incontinence, and overlapping chronic constipation occur more frequently in patients with OAB.

Conventional treatments of OAB generally include lifestyle modifications as a first course of action. Lifestyle modifications include eliminating bladder irritants (such as caffeine) from the diet, managing fluid intake, reducing weight, stopping smoking, and managing bowel regularity. Behavioral modifications include changing voiding habits (such as bladder training and delayed voiding), training pelvic floor muscles to improve strength and control of urethral sphincter, biofeedback and techniques for urge suppression. Medications are considered a second-line treatment for OAB. These include anti-cholinergic medications (oral, transdermal patch, and gel) and oral beta-3 adrenergic agonists. However, anti-cholinergics are frequently associated with bothersome, systemic side effects including dry mouth, constipation, urinary retention, blurred vision, somnolence, and confusion. Studies have found that more than 50% of patients stop using anti-cholinergic medications within 90 days due to a lack of benefit, adverse events, or cost.

When these approaches are unsuccessful, third-line treatment options suggested by the American Urological Association include intradetrusor (bladder smooth muscle) injections of botulinum toxin (BTX), Percutaneous Tibial Nerve Stimulation (PTNS) and Sacral Nerve Stimulation (SNM). BTX is administered via a series of intradetrusor injections under cystoscopic guidance, but repeat injections of BTX are generally required every 4 to 12 months to maintain effect and BTX may undesirably result in urinary retention. A number or randomized controlled studies have shown some efficacy of BTX injections in OAB patients, but long-term safety and effectiveness of BTX for OAB is largely unknown.

PTNS therapy consists of weekly, 30-minute sessions over a period of 12 weeks, each session using electrical stimulation that is delivered from a hand-held stimulator to the sacral plexus via the tibial nerve. For patients who respond well and continue treatment, ongoing sessions, typically every 3-4 weeks, are needed to maintain symptom reduction. There is potential for declining efficacy if patients fail to adhere to the treatment schedule. Efficacy of PTNS has been demonstrated in a few randomized-controlled studies, however, there is limited data on PTNS effectiveness beyond 3-years and PTNS is not recommended for patients seeking a cure for urge urinary incontinence (UUI) (e.g., 100% reduction in incontinence episodes) (EAU Guidelines).

II. Sacral Neuromodulation

SNM is an established therapy that provides a safe, effective, reversible, and long-lasting treatment option for the management of urge incontinence, urgency-frequency, and non-obstructive urinary retention. SNM therapy involves the use of mild electrical pulses to stimulate the sacral nerves located in the lower back. Electrodes are placed next to a sacral nerve, usually at the S3 level, by inserting the electrode leads into the corresponding foramen of the sacrum. The electrodes are inserted subcutaneously and are subsequently attached to an implantable pulse generator (IPG). The safety and effectiveness of SNM for the treatment of OAB, including durability at five years for both urge incontinence and urgency-frequency patients, is supported by multiple studies and is well-documented. SNM has also been approved to treat chronic fecal incontinence in patients who have failed or are not candidates for more conservative treatments.

A. Implantation of Sacral Neuromodulation System

Currently, SNM qualification has a trial phase, and is followed if successful by a permanent implant. The trial phase is a test stimulation period where the patient is allowed to evaluate whether the therapy is effective. Typically, there are two techniques that are utilized to perform the test stimulation. The first is an office-based procedure termed the Percutaneous Nerve Evaluation (PNE) and the other is a staged trial.

In the PNE, a foramen needle is typically used first to identify the optimal stimulation location, usually at the S3 level, and to evaluate the integrity of the sacral nerves. Motor and sensory responses are used to verify correct needle placement, as described in Table 1 below. A temporary stimulation lead (a unipolar electrode) is then placed near the sacral nerve under local anesthesia. This procedure can be performed in an office setting without fluoroscopy. The temporary lead is then connected to an external pulse generator (EPG) taped onto the skin of the patient during the trial phase. The stimulation level can be adjusted to provide an optimal comfort level for the particular patient. The patient will monitor his or her voiding for 3 to 7 days to see if there is any symptom improvement. The advantage of the PNE is that it is an incision free procedure that can be performed in the physician's office using local anesthesia. The disadvantage is that the temporary lead is not securely anchored in place and has the propensity to migrate away from the nerve with physical activity and thereby cause failure of the therapy. If a patient fails this trial test, the physician may still recommend the staged trial as described below. If the PNE trial is positive, the temporary trial lead is removed and a permanent quadri-polar tined lead is implanted along with an IPG under general anesthesia.

A staged trial involves the implantation of the permanent quadri-polar tined stimulation lead into the patient from the start. It also requires the use of a foramen needle to identify the nerve and optimal stimulation location. The lead is implanted near the S3 sacral nerve and is connected to an EPG via a lead extension. This procedure is performed under fluoroscopic guidance in an operating room and under local or general anesthesia. The EPG is adjusted to provide an optimal comfort level for the patient and the patient monitors his or her voiding for up to two weeks. If the patient obtains meaningful symptom improvement, he or she is considered a suitable candidate for permanent implantation of the IPG under general anesthesia, typically in the upper buttock area, as shown in FIGS. 1 and 3A.

TABLE 1

Motor and Sensory Responses of SNM

at Different Sacral Nerve Roots

Response

Nerve Innervation
Pelvic Floor
Foot/calf/leg
Sensation

S2 -Primary somatic
“Clamp” *
Leg/hip rotation,
Contraction

contributor of
of anal
plantar flexion of
of base of

pudendal nerve for
sphincter
entire foot, con-
penis, vagina

external sphincter,

traction of calf

leg, foot

S3 - Virtually all
“bellows” **
Plantar flexion
Pulling in

pelvic autonomic
of perineum
of great toe,
rectum, extend-

functions and

occasionally
ing forward to

striated mucle

other toes
scrotum or

(levetor ani)

labia

S4 - Pelvic
“bellows” **
No lower
Pulling in

autonomic and

extremity
rectum only

somatic; No leg

motor

pr foot

stimulation

* Clamp: contraction of anal sphincter and, in males, retraction of base of penis. Move buttocks aside and look for anterior/posterior shortening of the perineal structures.

** Bellows: lifting and dropping of pelvic floor. Look for deepening and flattening of buttock groove

In regard to measuring outcomes for SNM treatment of voiding dysfunction, the voiding dysfunction indications (e.g., urge incontinence, urgency-frequency, and non-obstructive urinary retention) are evaluated by unique primary voiding diary variables. The therapy outcomes are measured using these same variables. SNM therapy is considered successful if a minimum of 50% improvement occurs in any of primary voiding diary variables compared with the baseline. For urge incontinence patients, these voiding diary variables may include: number of leaking episodes per day, number of heavy leaking episodes per day, and number of pads used per day. For patients with urgency-frequency, primary voiding diary variables may include: number of voids per day, volume voided per void and degree of urgency experienced before each void. For patients with retention, primary voiding diary variables may include: catheterized volume per catheterization and number of catheterizations per day. For fecal incontinence patients, the outcome measures captured by the voiding diary include: number of leaking episodes per week, number of leaking days per week, and degree of urgency experienced before each leak.

The mechanism of action of SNM is multifactorial and impacts the neuro-axis at several different levels. In patients with OAB, it is believed that pudendal afferents can activate the inhibitory reflexes that promote bladder storage by inhibiting the afferent limb of an abnormal voiding reflex. This blocks input to the pontine micturition center, thereby restricting involuntary detrusor contractions without interfering with normal voiding patterns. For patients with urinary retention, SNM is believed to activate the pudendal nerve afferents originating from the pelvic organs into the spinal cord. At the level of the spinal cord, pudendal afferents may turn on voiding reflexes by suppressing exaggerated guarding reflexes, thus relieving symptoms of patients with urinary retention so normal voiding can be facilitated. In patients with fecal incontinence, it is hypothesized that SNM stimulates pudendal afferent somatic fibers that inhibit colonic propulsive activity and activates the internal anal sphincter, which in turn improves the symptoms of fecal incontinence patients.

The present invention relates to a system adapted to deliver neurostimulation to targeted nerve tissues in a manner that results in partial or complete activation of the target nerve fibers, causes the augmentation or inhibition of neural activity in nerves, potentially the same or different than the stimulation target, that control the organs and structures associated with bladder and bowel function.

B. EMG Assisted Neurostimulation Lead Placement and Programming

While conventional sacral nerve stimulation approaches have shown efficacy in treatment of bladder and bowel related dysfunctions, there exists a need to improve positioning of the neurostimulation leads and consistency between the trial and permanent implantation positions of the lead as well as to improve methods of programming. Neurostimulation relies on consistently delivering therapeutic stimulation from a pulse generator, via one or more neurostimulation electrodes, to particular nerves or targeted regions. The neurostimulation electrodes are provided on a distal end of an implantable lead that can be advanced through a tunnel formed in patient tissue. Implantable neurostimulation systems provide patients with great freedom and mobility, but it may be easier to adjust the neurostimulation electrodes of such systems before they are surgically implanted. It is desirable for the physician to confirm that the patient has desired motor and/or sensory responses before implanting an IPG. For at least some treatments (including treatments of at least some forms of urinary and/or fecal dysfunction), demonstrating appropriate motor responses may be highly beneficial for accurate and objective lead placement while the sensory response may not be required or not available (e.g., patient is under general anesthesia).

Placement and calibration of the neurostimulation electrodes and implantable leads sufficiently close to specific nerves can be beneficial for the efficacy of treatment. Accordingly, aspects and embodiments of the present disclosure are directed to aiding and refining the accuracy and precision of neurostimulation electrode placement. Further, aspects and embodiments of the present disclosure are directed to aiding and refining protocols for setting therapeutic treatment signal parameters for a stimulation program implemented through implanted neurostimulation electrodes.

Prior to implantation of the permanent device, patients may undergo an initial testing phase to estimate potential response to treatment. As discussed above, PNE may be done under local anesthesia, using a test needle to identify the appropriate sacral nerve(s) according to a subjective sensory response by the patient. Other testing procedures can involve a two-stage surgical procedure, where a quadri-polar tined lead is implanted for a testing phase (Stage 1) to determine if patients show a sufficient reduction in symptom frequency, and if appropriate, proceeding to the permanent surgical implantation of a neuromodulation device. For testing phases and permanent implantation, determining the location of lead placement can be dependent on subjective qualitative analysis by either or both of a patient or a physician.

In exemplary embodiments, determination of whether or not an implantable lead and neurostimulation electrode is located in a desired or correct location can be accomplished through use of electromyography (“EMG”), also known as surface electromyography. EMG, is a technique that uses an EMG system or module to evaluate and record electrical activity produced by muscles, producing a record called an electromyogram. EMG detects the electrical potential generated by muscle cells when those cells are electrically or neurologically activated. The signals can be analyzed to detect activation level or recruitment order. EMG can be performed through the skin surface of a patient, intramuscularly or through electrodes disposed within a patient near target muscles, or using a combination of external and internal structures. When a muscle or nerve is stimulated by an electrode, EMG can be used to determine if the related muscle is activated, (i.e. whether the muscle fully contracts, partially contracts, or does not contract) in response to the stimulus. Accordingly, the degree of activation of a muscle can indicate whether an implantable lead or neurostimulation electrode is located in the desired or correct location on a patient. Further, the degree of activation of a muscle can indicate whether a neurostimulation electrode is providing a stimulus of sufficient strength, amplitude, frequency, or duration to affect a treatment regimen on a patient. Thus, use of EMG provides an objective and quantitative means by which to standardize placement of implantable leads and neurostimulation electrodes, reducing the subjective assessment of patient sensory responses.

In some approaches, positional titration procedures may optionally be based in part on a paresthesia or pain-based subjective response from a patient. In contrast, EMG triggers a measurable and discrete muscular reaction. As the efficacy of treatment often relies on precise placement of the neurostimulation electrodes at target tissue locations and the consistent, repeatable delivery of neurostimulation therapy, using an objective EMG measurement can substantially improve the utility and success of SNM treatment. The measurable muscular reaction can be a partial or a complete muscular contraction, including a response below the triggering of an observable motor response, such as those shown in Table 1, depending on the stimulation of the target muscle. In addition, by utilizing a trial system that allows the neurostimulation lead to remain implanted for use in the permanently implanted system, the efficacy and outcome of the permanently implanted system is more consistent with the results of the trial period, which moreover leads to improved patient outcomes.

C. Example System Embodiments

FIG. 1 schematically illustrates example nerve stimulation system setups, which includes a setup for use in a trial neurostimulation system 200 and a setup for use in a permanently implanted neurostimulation system 100, in accordance with aspects of the invention. The EPG 80 and IPG 50 are each compatible with and wirelessly communicate with a clinician programmer (CP) 60 and a patient remote 70, which are used in positioning and/or programming the trial neurostimulation system 200 and/or permanently implanted system 100 after a successful trial. As discussed above, the system utilizes a cable set and EMG sensor patches in the trial system setup 100 to facilitate lead placement and neurostimulation programming. CP can include specialized software, specialized hardware, and/or both, to aid in lead placement, programming, re-programming, stimulation control, and/or parameter setting. In addition, each of the IPG and the EPG allows the patient at least some control over stimulation (e.g., initiating a pre-set program, increasing or decreasing stimulation), and/or to monitor battery status with the patient remote. This approach also allows for an almost seamless transition between the trial system and the permanent system.

In one aspect, the CP 60 is used by a physician to adjust the settings of the EPG and/or IPG while the lead is implanted within the patient. The CP can be a tablet computer used by the clinician to program the IPG, or to control the EPG during the trial period. The CP can also include capability to record stimulation-induced electromyograms to facilitate lead placement and programming. The patient remote 70 can allow the patient to turn the stimulation on or off, or to vary stimulation from the IPG while implanted, or from the EPG during the trial phase.

In another aspect, the CP 60 has a control unit which can include a microprocessor and specialized computer-code instructions for implementing methods and systems for use by a physician in deploying the treatment system and setting up treatment parameters. The CP generally includes a graphical user interface, an EMG module, an EMG input that can couple to an EMG output stimulation cable, an EMG stimulation signal generator, and a stimulation power source. The stimulation cable can further be configured to couple to any or all of an access device (e.g., a foramen needle), a treatment lead of the system, or the like. The EMG input may be configured to be coupled with one or more sensory patch electrode(s) for attachment to the skin of the patient adjacent a muscle (e.g., a muscle enervated by a target nerve). Other connectors of the CP may be configured for coupling with an electrical ground or ground patch, an electrical pulse generator (e.g., an EPG or an IPG), or the like. As noted above, the CP can include a module with hardware and computer-code to execute EMG analysis, where the module can be a component of the control unit microprocessor, a pre-processing unit coupled to or in-line with the stimulation and/or sensory cables, or the like.

In other aspects, the CP 60 allows the clinician to read the impedance of each electrode contact whenever the lead is connected to an EPG, an IPG or a CP to ensure reliable connection is made and the lead is intact. This may be used as an initial step in both positioning the lead and in programming the leads to ensure the electrodes are properly functioning. The CP 60 is also able to save and display previous (e.g., up to the last four) programs that were used by a patient to help facilitate re-programming. In some embodiments, the CP 60 further includes a USB port for saving reports to a USB drive and a charging port. The CP is configured to operate in combination with an EPG when placing leads in a patient body as well with the IPG during programming. The CP can be electronically coupled to the EPG during test simulation through a specialized cable set or through wireless communication, thereby allowing the CP to configure, modify, or otherwise program the electrodes on the leads connected to the EPG. The CP may also include physical on/off buttons to turn the CP on and off and/or to turn stimulation on and off.

The electrical pulses generated by the EPG and IPG are delivered to one or more targeted nerves via one or more neurostimulation electrodes at or near a distal end of each of one or more leads. The leads can have a variety of shapes, can be a variety of sizes, and can be made from a variety of materials, which size, shape, and materials can be tailored to the specific treatment application. While in this embodiment, the lead is of a suitable size and length to extend from the IPG and through one of the foramen of the sacrum to a targeted sacral nerve, in various other applications, the leads may be, for example, implanted in a peripheral portion of the patient's body, such as in the arms or legs, and can be configured to deliver electrical pulses to the peripheral nerve such as may be used to relieve chronic pain. It is appreciated that the leads and/or the stimulation programs may vary according to the nerves being targeted.

FIGS. 2A-2C show diagrams of various nerve structures of a patient, which may be used in neurostimulation treatments, in accordance with aspects of the invention. FIG. 2A shows the different sections of the spinal cord and the corresponding nerves within each section. The spinal cord is a long, thin bundle of nerves and support cells that extend from the brainstem along the cervical cord, through the thoracic cord and to the space between the first and second lumbar vertebra in the lumbar cord. Upon exiting the spinal cord, the nerve fibers split into multiple branches that innervate various muscles and organs transmitting impulses of sensation and control between the brain and the organs and muscles. Since certain nerves may include branches that innervate certain organs, such as the bladder, and branches that innervate certain muscles of the leg and foot, stimulation of the nerve at or near the nerve root near the spinal cord can stimulate the nerve branch that innervate the targeted organ, which may also result in muscle responses associated with the stimulation of the other nerve branch. Thus, by monitoring for certain muscle responses, such as those in Table 1, either visually, through the use of EMG as described herein or both, the physician can determine whether the targeted nerve is being stimulated. While stimulation at a certain level may evoke robust muscle responses visible to the naked eye, stimulation at a lower level (e.g. sub-threshold) may still provide activation of the nerve associated with the targeted organ while evoking no corresponding muscle response or a response only visible with EMG. In some embodiments, this low level stimulation also does not cause any paresthesia. This is advantageous as it allows for treatment of the condition by neurostimulation without otherwise causing patient discomfort, pain or undesired muscle responses.

FIG. 2B shows the nerves associated with the lower back section, in the lower lumbar cord region where the nerve bundles exit the spinal cord and travel through the sacral foramens of the sacrum. In some embodiments, the neurostimulation lead is advanced through the foramen until the neurostimulation electrodes are positioned at the anterior sacral nerve root, while the anchoring portion of the lead proximal of the stimulation electrodes are generally disposed dorsal of the sacral foramen through which the lead passes, so as to anchor the lead in position. FIG. 2C shows detail views of the nerves of the lumbosacral trunk and the sacral plexus, in particular, the S1-S5 nerves of the lower sacrum. The S3 sacral nerve is of particular interest for treatment of bladder related dysfunction, and in particular OAB.

FIG. 3A schematically illustrates an example of a fully implanted neurostimulation system 100 adapted for sacral nerve stimulation. Neurostimulation system 100 includes an IPG implanted in a lower back region and connected to a neurostimulation lead extending through the S3 foramen for stimulation of the S3 sacral nerve. The lead is anchored by a tined anchor portion 10 that maintains a position of a set of neurostimulation electrodes 30 along the targeted nerve, which in this example, is the anterior sacral nerve root S3 which enervates the bladder so as to provide therapy for various bladder related dysfunctions. While this embodiment is adapted for sacral nerve stimulation, it is appreciated that similar systems can be used in treating patients with, for example, chronic, severe, refractory neuropathic pain originating from peripheral nerves or various urinary dysfunctions or still further other indications. Implantable neurostimulation systems can be used to either stimulate a target peripheral nerve or the posterior epidural space of the spine.

Properties of the electrical pulses can be controlled via a controller of the implanted pulse generator. In some embodiments, these properties can include, for example, the frequency, amplitude, pattern, duration, or other aspects of the electrical pulses. These properties can include, for example, a voltage, a current, or the like. This control of the electrical pulses can include the creation of one or more electrical pulse programs, plans, or patterns, and in some embodiments, this can include the selection of one or more pre-existing electrical pulse programs, plans, or patterns. In the embodiment depicted in FIG. 3A, the implantable neurostimulation system 100 includes a controller in the IPG having one or more pulse programs, plans, or patterns that may be pre-programmed or created as discussed above. In some embodiments, these same properties associated with the IPG may be used in an EPG of a partly implanted trial system used before implantation of the permanent neurostimulation system 100.

FIG. 3B shows a schematic illustration of a trial neurostimulation system 200 utilizing an EPG patch 81 adhered to the skin of a patient, particularly to the abdomen of a patient, the EPG 80 being encased within the patch. In one aspect, the lead is hardwired to the EPG, while in another the lead is removably coupled to the EPG through a port or aperture in the top surface of the flexible patch 81. Excess lead can be secured by an additional adherent patch. In one aspect, the EPG patch is disposable such that the lead can be disconnected and used in a permanently implanted system without removing the distal end of the lead from the target location. Alternatively, the entire system can be disposable and replaced with a permanent lead and IPG. When the lead of the trial system is implanted, an EMG obtained via the CP using one or more sensor patches can be used to ensure that the leads are placed at a location proximate to the target nerve or muscle, as discussed previously.

In some embodiments, the trial neurostimulation system utilizes an EPG 80 within an EPG patch 81 that is adhered to the skin of a patient and is coupled to the implanted neurostimulation lead 20 through a lead extension 22, which is coupled with the lead 20 through a connector 21. This extension and connector structure allows the lead to be extended so that the EPG patch can be placed on the abdomen and allows use of a lead having a length suitable for permanent implantation should the trial prove successful. This approach may utilize two percutaneous incisions, the connector provided in the first incision and the lead extensions extending through the second percutaneous incision, there being a short tunneling distance (e.g., about 10 cm) there between. This technique may also minimize movement of an implanted lead during conversion of the trial system to a permanently implanted system.

In one aspect, the EPG unit is wirelessly controlled by a patient remote and/or the CP in a similar or identical manner as the IPG of a permanently implanted system. The physician or patient may alter treatment provided by the EPG through use of such portable remotes or programmers and the treatments delivered are recorded on a memory of the programmer for use in determining a treatment suitable for use in a permanently implanted system. The CP can be used in lead placement, programming and/or stimulation control in each of the trial and permanent nerve stimulation systems. In addition, each nerve stimulation system allows the patient to control stimulation or monitor battery status with the patient remote. This configuration is advantageous as it allows for an almost seamless transition between the trial system and the permanent system. From the patient's viewpoint, the systems will operate in the same manner and be controlled in the same manner, such that the patient's subjective experience in using the trial system more closely matches what would be experienced in using the permanently implanted system. Thus, this configuration reduces any uncertainties the patient may have as to how the system will operate and be controlled such that the patient will be more likely to receive a trial system or a permanent system.

As shown in the detailed view of FIG. 3B, the EPG 80 is encased within a flexible laminated patch 81, which include an aperture or port through which the EPG 80 is connected to the lead extension 22. The patch may further an “on/off” button 83 with a molded tactile detail to allow the patient to turn the EPG on and/or off through the outside surface of the adherent patch 81. The underside of the patch 81 is covered with a skin-compatible adhesive 82 for continuous adhesion to a patient for the duration of the trial period. For example, a breathable strip having skin-compatible adhesive 82 would allow the EPG 80 to remain attached to the patient continuously during the trial, which may last over a week, typically two weeks to four weeks, or even longer.

While the above described systems provide considerable improvements in locating an optimal position of the lead and fine tuning lead placement and an optimal neurostimulation program is determined, it is imperative after the lead is successfully placed to ensure that the lead position is maintained over the course of therapy. Should the neurostimulation lead migrate, even a small axial distance, the electrodes may shift from the targeted nerve tissue such that the neurostimulation treatment may not delivery consistent results or no longer provide therapeutic effect without reprogramming or repositioning the lead.

In a fully implantable system, the pulse generator is implanted in the patient in an area having adequate size to comfortably contain the pulse generator, typically in a lower back region or lower abdominal region. Since the electrodes may need to be located a considerable distance from the implantable pulse generator, depending on the treatment or therapy being delivered, a neurostimulation lead is used to deliver the electrical pulses from the implanted pulse generator to the electrodes. While many such systems have proven effective, studies have shown that over time the neurostimulation lead may move, particularly when the lead extends through areas subject to movement. Such movement can dislocate the electrodes from the targeted location, such that the neurostimulation treatment becomes ineffective, requiring adjustment or replacement of the lead. Therefore, it is desirable to provide an anchoring device on the stimulation lead in such systems to inhibit movement of the lead and dislocation of the electrodes. While conventional neurostimulation has developed various anchoring mechanisms, such mechanisms often complicate the implantation procedure, undesirably increase the delivery profile of the lead, are difficult to replace or remove, or have proven ineffective.

FIG. 4 illustrates an example neurostimulation system 100 that is fully implantable and adapted for sacral nerve stimulation treatment. The implantable system 100 includes an IPG 90 that is coupled to a neurostimulation lead 20 that includes a group of neurostimulation electrodes 30 at a distal end of the lead. The lead includes a lead anchor portion 10 with a series of tines extending radially outward so as to anchor the lead and maintain a position of the neurostimulation lead 20 after implantation. The lead 20 may further include one or more radiopaque markers (e.g., silicon markers) 25 to assist in locating and positioning the lead using visualization techniques such as fluoroscopy. In some embodiments, the IPG provides monopolar or bipolar electrical pulses that are delivered to the targeted nerves through one or more neurostimulation electrodes. In sacral nerve stimulation, the lead is typically implanted through the S3 foramen as described herein.

As can be seen in FIG. 4, the neurostimulation lead 20 includes a plurality of neurostimulation electrodes 30 at a distal end of the lead and the anchor 10 is disposed just proximal of the electrodes 30. Typically, the anchor is disposed near and proximal of the plurality of electrodes so as to provide anchoring of the lead relatively close to the electrodes. This configuration is also advantageous as it allows for testing of the neurostimulation electrodes during implantation before deploying of the anchor (as described below), which allows the optimal location of the neurostimulation electrodes to be determined before the lead is anchored in place. As shown, the anchor 10 includes an anchor body 12 helically swept about the lead body and a plurality of tines 14 extending laterally outward from the helical body 12. This configuration is advantageous over conventional anchor devices as it provides a plurality of tines distributed both circumferentially and axially about the lead while extending from a common anchor body, thereby simplifying attachment and replacement of the anchoring tines. In addition, since the anchor body extends helically about the lead boy, this allows the flexibility of the lead body to be retained in the tined area. In one aspect, the anchor is constructed of a suitable material that is biocompatible as well as compatible with the material of which the lead body is formed and that is sufficiently flexible to provide anchoring force against the tissue without damaging the tissue.

In one aspect, the IPG is rechargeable wirelessly through conductive coupling by use of a charging device 50 (CD), which is a portable device powered by a rechargeable battery to allow patient mobility while charging. The CD is used for transcutaneous charging of the IPG through RF induction. The CD can either be patched to the patient's skin using an adhesive or can be held in place using a belt 53 or by an adhesive patch 52, such as shown in the schematic of FIG. 1. The CD may be charged by plugging the CD directly into an outlet or by placing the CD in a charging dock or station 51 that connects to an AC wall outlet or other power source

FIG. 5A-5C show detail views of the IPG and its internal components. In some embodiments, the pulse generator can generate one or more non-ablative electrical pulses that are delivered to a nerve to control pain or cause some other desired effect, for example to inhibit, prevent, or disrupt neural activity for the treatment of OAB or bladder related dysfunction. In some applications, the pulses having a pulse amplitude in a range between 0 mA to 1,000 mA, 0 mA to 100 mA, 0 mA to 50 mA, 0 mA to 25 mA, and/or any other or intermediate range of amplitudes may be used. One or more of the pulse generators can include a processor and/or memory adapted to provide instructions to and receive information from the other components of the implantable neurostimulation system. The processor can include a microprocessor, such as a commercially available microprocessor from Intel® or Advanced Micro Devices, Inc.®, or the like. An IPG may include an energy storage feature, such as one or more capacitors or a battery, one or more batteries, and typically includes a wireless charging unit.

One or more properties of the electrical pulses can be controlled via a controller of the IPG or EPG. In some embodiments, these properties can include, for example, the frequency, amplitude, pattern, duration, or other aspects of the timing and magnitude of the electrical pulses. These properties can further include, for example, a voltage, a current, or the like. This control of the electrical pulses can include the creation of one or more electrical pulse programs, plans, or patterns, and in some embodiments, this can include the selection of one or more pre-existing electrical pulse programs, plans, or patterns. In one aspect, the IPG 90 includes a controller having one or more pulse programs, plans, or patterns that may be created and/or pre-programmed. In some embodiments, the IPG can be programmed to vary stimulation parameters including pulse amplitude in a range from 0 mA to 10 mA, pulse width in a range from 50 μs to 500 μs, pulse frequency in a range from 5 Hz to 250 Hz, stimulation modes (e.g., continuous or cycling), and electrode configuration (e.g., anode, cathode, or off), to achieve the optimal therapeutic outcome specific to the patient. In particular, this allows for an optimal setting to be determined for each patient even though each parameter may vary from person to person.

As shown in FIGS. 5A-5B, the IPG 90 may include a header portion 91 at one end and a ceramic portion 94 at the opposite end. The header portion 91 houses a feed through assembly 92 and connector stack 93, while the ceramic case portion 94 houses an antennae assembly 96 to facilitate wireless communication with the clinician program, the patient remote, and/or a charging coil to facilitate wireless charging with the CD. The remainder of the IPG is covered with a titanium case portion 97, which encases the printed circuit board, memory and controller components that facilitate the electrical pulse programs described above. In the example shown in FIG. 5C, the header portion of the IPG includes a four-pin feed-through assembly 92 that couples with the connector stack 93 in which the proximal end of the lead is coupled. The four pins correspond to the four electrodes of the neurostimulation lead. In some embodiments, a Balseal® connector block is electrically connected to four platinum/iridium alloy feed-through pins which are brazed to an alumina ceramic insulator plate along with a titanium alloy flange. This feed-through assembly is laser seam welded to a titanium-ceramic brazed case to form a complete hermetic housing for the electronics.

In the IPG shown in FIG. 5A, the ceramic and titanium brazed case is utilized on one end of the IPG where the ferrite coil and PCB antenna assemblies are positioned. A reliable hermetic seal is provided via a ceramic-to-metal brazing technique. The zirconia ceramic may comprise a 3Y-TZP (3 mol percent Yttria-stabilized tetragonal Zirconia Polycrystals) ceramic, which has a high flexural strength and impact resistance and has been commercially utilized in a number of implantable medical technologies. It will be appreciated, however, that other ceramics or other suitable materials may be used for construction of the IPG.

Utilization of ceramic material provides an efficient, radio-frequency-transparent window for wireless communication with the external patient remote and clinician's programmer as the communication antenna is housed inside the hermetic ceramic case. This ceramic window has further facilitated miniaturization of the implant while maintaining an efficient, radio-frequency-transparent window for long term and reliable wireless communication between the IPG and external controllers, such as the patient remote and CP. The IPG's wireless communication is generally stable over the lifetime of the device, unlike prior art products where the communication antenna is placed in the header outside the hermetic case. The communication reliability of such prior art devices tends to degrade due to the change in dielectric constant of the header material in the human body over time. The ferrite core is part of the charging coil assembly 95, shown in FIG. 5B, which is positioned inside the ceramic case 94. The ferrite core concentrates the magnetic field flux through the ceramic case as opposed to the metallic case portion 97. This configuration maximizes coupling efficiency, which reduces the required magnetic field and in turn reduces device heating during charging. In particular, because the magnetic field flux is oriented in a direction perpendicular to the smallest metallic cross section area, heating during charging is minimized. It is appreciated that these IPG structures and neurostimulation leads are described for illustrative purposes and that the anchoring structures described herein may be used with various other neurostimulation leads and IPGs in accordance with the principles of the invention.

The proximal end of the lead include a plurality of conductors corresponding to the plurality of electrodes at the distal end that electrically couple with corresponding contacts within the connector stack 93 within the header portion 91, thereby electrically connecting the IPG contacts with the neurostimulation electrodes 30 of the lead 20 for delivery of neurostimulation therapy. Although movement in the lower back region where the IPG is located is limited, the lead may still be subjected to forces and slight movement for various reasons, for example due to changes in tissue volume, trauma to the tissue region in which the system is implanted, or routine muscle movements. When these forces and movements are repeated over time, the connection between the proximal portion of the lead and the IPG may become compromised due to the fatigue caused by repeated stress and strain at the point of the stiffness mismatch that exists at the junction of the flexible lead and the IPG header portion 91. In some embodiments, a strain relief element that extends along a proximal portion of the lead where the lead exits the header portion 91 is included to provide strain relief at the junction of the proximal portion of the lead and the IPG so as to maintain integrity of the electrical connection and lengthen the useful life of the lead.

In some embodiments, the system includes a strain relief element that extends along a proximal portion of the lead adjacent the head portion of the IPG. The strain relief element may be disposed about the proximal portion of the lead or integrated into the lead itself. The strain relief element may include a proximal base that attaches or interfaces with a head portion of the IPG. In some embodiments, the strain relief element is a helical element that extends about the proximal portion of the lead. The strain relief element may be formed of a metal (e.g. stainless steel), polymer or any other suitable material. The proximal portion of the lead may include a recessed portion in which the strain relief element reside so that the outer surface of the strain relief element is substantially flush or about flush with the outer surface of the lead. Alternatively, the strain relief element may be applied to a non-recessed or standard sized portion anywhere along the lead body as needed. Typically, the strain relief element is a length within a range of about 1 inch to 6 inches so as to reduce flexing or bending of the proximal portion of the lead near the IPG, which can compromise the electrical connection over time. In one aspect, the strain relief element is formed so as to have an increased stiffness along a longitudinal axis so as to inhibit lateral bending of the proximal portion of the lead. Any of the aspects described herein in regard to the structure and design of the helical anchor body may be applicable to the strain relief element.

In some embodiments, the strain relief element 27 comprises a helical structure that extends along a proximal portion of the lead 20 adjacent where the lead 20 is inserted into the head portion 91 of the IPG 90, such as shown in FIG. 6C. The strain relief element 27 may include a proximal base 28 configured to securely attach to the header portion 91 and a helical portion 29 that encircles a proximal portion of the lead. Typically, the helical portion 29 exhibits increased stiffness as compared to the lead such that the helical portion 29 withstands any stresses or forces applied to the lead in the proximal region. Furthermore the helical structure limits the minimum bending radius in the region, which prevents sharp bends that can potentially damage the lead at the strain relief location. The strain relief element may be formed of any suitable, biocompatible material, including polymers or various metals (e.g. stainless steel, Nitinol). The strain relief member can be attached to the lead at manufacturing or alternatively, loaded onto the lead at the time of implant and attachment to the IPG connector.

In one aspect, the strain relief element is sufficiently thin such that its low profile does not substantially increase the maximum cross-section or crossing profile of the lead through the sheath. In some embodiments, the proximal portion of the lead may have a reduced diameter and dimension so as to fittingly receive the strain relief member so that the strain relief member is substantially flush with the outer surface of the lead distal of the strain relief member.

FIGS. 6A-6B illustrate detail views of example strain relief members 27 and 27′, respectively, each including a proximal base 28 for securing to the IPG header portion and a helical strain relief portion 29 for wrapping about the proximal portion of the lead 20. The proximal base portion 28 may be sized and dimensioned according to a particular IPG header portion. In one aspect, the helical portions 29 can be configured to provide variable stiffness along the length of the proximal portion of the lead. For example, the helical portions 29 can be of variable thickness along the length of the strain relief to provide gradual stiffness transition in the region and/or the helical portions can vary in pitch and/or width along the length of the strain relief to provide gradual stiffness and limit the bend radius in the region. In another aspect, the strain relief element 27 can include one or more tines (not shown), similar to the anchors described herein, so as to provide tissue fixation to the strain relief portion and further inhibit movement or migration of the proximal portion of the lead.

III. Lead Affixation by Helical Anchors

FIG. 7 illustrates a detail view of a neurostimulation lead 20, similar to that in FIG. 4, with an anchoring body 10 mounted on an anchoring portion 22 of the lead, shown in the deployed configuration. As can be seen, the helical body 12 is helically swept about a central longitudinal axis for placement on the lead body and the plurality of tines 14 are distributed along the helical body 12 extending laterally outward from the central axis and angled in a proximal direction. As shown in the detail view of 10FIG. 8, the plurality of tines 14 of the anchoring body are distributed so as to be radially offset from one another at regular intervals (e.g. 30°, 45°, 90°) within a range of intervals, such as between 10° and 90°, so that the plurality of tines extend outward in different directions circumferentially about the central axis. This distributes any anchoring forces about the lead body so as to improve anchoring of the lead.

In one aspect, the anchor 10 includes a radiopaque strip 16 embedded within the helical body 12 to allow localization of the anchor 10 through visualization techniques. The radiopaque strip may be fabricated from any radiopaque material, such as a platinum alloy (e.g. Pt/lr), so as to visible using standard visualization techniques. Such a strip is advantageous as it facilitates positioning of the lead at the targeted location. In other embodiments, the helical body may be formed of a material that is radiopaque, for example a radiopaque material may be blended into a polymer material of which the anchor is formed.

FIGS. 9A-9B illustrate a neurostimulation lead having an attached anchor in a delivery configuration and a deployed configuration, respectively. In FIG. 9A, the plurality of tines 14 are folded against the body of the lead 20 without overlapping each other or an adjacent section of the helical body. Typically, the tines are constrained in the delivery configuration by an outer sheath (not shown) while the lead is advanced through a tunnel in a tissue to the targeted location. The helical body is swept at a pitch to allow sufficient space between adjacent turns of the helical body for a tab to fold inward against the lead boy, which allows for a reduced delivery profile. In one aspect, the cross section of the anchor is less than 2.0 mm, sufficiently small to be delivered through a 5 French sheath. In one aspect, the lead body includes a recessed portion 22 having a reduced outer diameter, in which the helical body 12 is attached. This feature facilitates coupling between the anchor 10 and the lead body 20 as the proximal and distal ends of the anchor abut against the proximal and distal ends of the recessed portion and allow for a reduced cross-section or crossing profile of the anchor portion of the lead. Once delivery of the electrodes to the target location is confirmed, the sheath may be withdrawn proximally, thereby allowing the plurality of tines to resiliently return to the deployed configuration toward which they are biased, as shown in FIG. 9B.

FIGS. 10A-10B illustrate detail views of the anchor 10 shown in FIG. 9B in the deployed configuration. In this embodiment, the tines 14 are all inclined proximally. It is understood, however, that in other embodiments, the anchor 10 may be configured so that the tines are angled distally or proximally, extend perpendicular to the longitudinal axis of the helical body, or extend in multiple differing directions as desired for a particular application.

In one aspect, the anchor is fabricated from a material sufficiently stiff to exert adequate anchoring forces to maintain the lead in place, yet sufficiently flexibly to fold inward against the lead and to avoid damaging tissue should the lead be removed from the tissue. In some embodiments, the anchor is fabricated from a molded polyurethane having a shore hardness within a range between 50A and 80D, preferably about 70D. The helical body may have a width between 1.0 mm to 3.0 mm, preferably about 2.0 mm and a total length between 10 mm and 30 mm, preferably about 20 mm. The anchor is configured such that the crossing profile is less than 2.0 mm, preferably 1.7 mm or less, so that a lead having the anchor attached thereto can be delivered through a standard sheath, such as a 5 French sheath. In certain embodiments, the tines have a length between 1 mm and 3 mm, preferably about 1.8 mm; a width between 0.5 and 2.0 mm, preferably about 0.8 mm; and a thickness between 0.2 mm and 0.5 mm, preferably about 0.3 mm. In certain embodiments, the anchor includes between 10 and 20 tines, preferably about 12 to 16 tines, spaced apart along the length of the helical body so as to extend in different directions circumferentially about the lead. In some embodiments, the tines are all of the same length and angle in the same direction, while in other embodiments, the tines may be of varying lengths, widths and may angle in both proximal and distal directions. While it is advantageous to dimension any of the anchor described herein according to the above described configuration in order to facilitate delivery of the anchor through a 5 French sheath, it is appreciated that the anchor may be configured according to various other dimensions (length, number of tines, etc.) as desired for a particular application or neurostimulation lead.

FIGS. 10A-10B and 11A-11B illustrate example anchors, similar to that shown in FIG. 8, except the tines 14 are formed in differing shapes. For example, in one aspect, the tines may be formed such that an end face is angled or pointed, such as shown in FIG. 8. In another aspect, the tines can be formed in a generally rectangular shape, such as shown in FIGS. 10A-10B. In another aspect, the tines can be formed such that the corners and/or edges are curved, rounded or chamfered, such as shown in FIGS. 11A-11B. This feature may help reduce the possibility of trauma to adjacent tissues by corners or edges of the tines as they engage tissue during anchoring of the lead.

FIGS. 12A-12B illustrate an example anchor similar to that in FIG. 8 except the plurality of tines angle in both proximal and distal directions. As can be seen, the proximal most tines angle in a distal direction, while the remaining tines angle in a proximal direction. This aspect is useful in applications where the lead tends to experience forces in both proximal and distal directions. For example, while studies have shown that neurostimulation leads implanted through a sacral foramen experience primarily forces directed in a proximal direction, various other applications, such as a peripherally implanted lead in an arm or leg, may experience significant forces in both proximal and distal directions.

FIGS. 13A-13B illustrate an anchor 10 composed of multiple anchor sections 10′. As shown, the anchor consists of two sections joined together. The anchor sections 10′ may be modular allowing one or more anchor sections to be used on a lead, as needed for a particular lead or application. The anchor sections may include a means to attach or couple the sections to one another or may be bonded together by various methods known to one of skill in the art, such as by use of an adhesive, a mechanical or chemical coupling, or an oxidation bonding method. This feature may allow a user to customize an anchoring portion with as desired, according to differing lengths, as well as differing dimensions and/or directions of the tines.

FIG. 14A-14B illustrates an anchor 10 having a cork-screw type shape. The anchor includes a continuous helical flap having multiple sections defined by cuts into the helical flap into multiple sections that can fold toward the lead body without overlapping one another. In one aspect, the anchor 10 is formed from monolithically from a single integral component. For example, the anchor 10 may be formed from a cork-screw type structure in which the helical flap is separated into tines by wedge-shaped notches 15 cut into the helical flap to define multiple tines 14 that can fold down against the lead for delivery of the anchor through a constraining insertion sheath.

In another aspect, any of the anchors described herein may include one or more various other features, including: biodegradable tines, drug eluting tines, and flexible dish-like tines that open or collapse after a certain bend angle is reached to allow for easy insertion or retraction. In another aspect, the anchor may include a strip or embedded material that shield or disrupts MRI induced heating.

In one aspect, the anchor 10 includes one or more drug eluting components, that release one or more therapeutic compounds over a period of time after implantation. Such a drug eluting component may include a portion of the anchor, a strip intertwined along a length of the anchor, the material from which the anchor is formed, or a coating deposited on the anchor or portion thereof. For example, the drug or therapeutic compound can be sprayed onto the anchor, the anchor can be dipped in the drug or compound, or the drug or compound can be mixed into a polymer of which the anchor is formed. In some embodiments, the anchor may be formed of a bioabsorable or nonabsorable polymer material or a combination of a nonabsorable base coated with a layer of drug eluting polymer. In one aspect, the drug or therapeutic compound may be applied in order to promote release of the drug in particular direction, for example the drug or compound may be applied to promote isotropic or anisotropic release of the drug along the axis of the tines. The eluting drug may be selected to promote and shorten healing time in order to minimize risk of lead migration. Alternatively or in addition to, the anchor may be configured to elute various other drugs to provide various other therapeutic benefits. For example, the anchor 10 may be formed to elute a compound to promote fixation within the tissues, such as a biological adhesive or compound to promote tissue formation after implantation in order to further minimize risk of lead migration.

While in many of the embodiments shown, the tines are configured to protrude and fold along an axis parallel to the longitudinal axis along which the helical portion extends, in some embodiments, the anchor can be designed so that the tines fold inward along a helical or inclined axis. Such a configuration can allow the tines to be retracted by twisting the lead in one direction to facilitate removal of the lead and/or allow the tines to be further deployed by twisting the lead in an opposite direction. In other embodiments, such as those in which the tines fold along an axis parallel to the longitudinal axis, the tines may be sufficiently flexible and/or frangible to allow removal of the lead by merely retracting the lead with sufficient force.

In one aspect, the anchor may be formed by cutting a pattern into an integral piece of material, for example a shape-memory metal, such as Nitinol. For example, the anchor can be formed by laser cutting a helical pattern into a piece of tubing or a cylindrical piece of the material, the pattern corresponding to the anchor in the constrained configuration, such as shown in the example of FIG. 15B. The tines can then be supported on a mold or propped up by various other means so that the material can be heat set while the anchor is in the expanded configuration, such as shown in FIG. 15A. Typically, the pattern is defined so that the tines are distributed evenly along the length of the helical body with the tines extending out in a multi-radial direction along the sweep of the spiral to provide evenly distributed tissue fixation in all directions, as shown in FIG. 15C.

In one aspect, the helical base can be heat set to a smaller inside diameter than the lead body so as to provide an interference fit, which can then be twisted to open and then loaded onto the lead body. Upon release, the helical base automatically tightens onto the lead body providing a secure attachment to the lead. The spiral design is configured so that when the tines are folded down the tines do not overlap each other or the helical body of the anchor.

In another aspect, as shown in FIG. 15A, the anchor design can include one or more retention features 11, 13 at the proximal and distal ends, respectively, that enable precise loading of the anchor onto the device. In this embodiment, the proximal and distal retention features 11,13 are designed to abut against a corresponding proximal and distal end of a reduced diameter anchoring portion 22 of the lead in which the anchor 10 is received so as to affix the anchor 10 to the body of the lead 20 and prevent axial movement of the anchor 10 along the lead before, during and/or after delivery of the lead and deployment of the anchor 10. In another aspect, the proximal and distal retention features 11, 13 may be designed in various shapes (e.g. zig-zag, curved, angled) along the proximal and distal facing edges so as to interlock with corresponding shapes along the lead at the proximal and distal ends of the anchoring portion 22. This configuration is useful in preventing free rotational movement of the anchor 10 relative the lead body 20 or to assist in translating rotational movement to the anchor upon rotation of the lead.

In one aspect, the anchor 10 may be formed of any type of implantable biocompatible polymers. Radiopaque fillers such as barium sulfate, bismuth, and tungsten can be added to the polymer to make the tines radiopaque under x-ray. Alternatively, or in addition to, a ribbon of radiopaque metal such as gold or platinum can be imbedded into the body of the helix to add radiopacity to the tines. In another approach, the anchor may include one or more discrete radiopaque markers that can be used with visualization techniques for localization of the anchor or that can be used to determine when the tines are deployed. For example, by placing one of a pair of markers at the end of a tine and the other on the helical body directly adjacent the end of the tine, when the anchor is in the constrained configuration, separation of the pair of markers can indicate when the tines are deployed, as well as the extent of their deployment within the tissue.

FIG. 16A illustrate another approach by which the anchor 10 can be formed. As shown in FIG. 16A, the anchor may be cut from a length of extruded polymer tubing, for example by laser cutting. The tines can be subsequently shaped to have an outwardly protruding bias through a heat set or reflow process. For example, the anchor 10 can be mounted on an internal mold (not shown) that props up the tines in an outwardly protruding configuration corresponding to the deployed anchor configuration and the polymer is heated and allowed to set. After setting, the tines 14 of the anchor 10 are biased towards the deployed configuration, such as shown in FIG. 16B. In one aspect, this heating and reflow process can also be used to incorporate one or more radiopaque markers, such as a Pt/Ir wire or ribbon wrapped at the same pitch as the helix. In another aspect, the polymer tubing extrusion can incorporate a ribbon or coil (e.g. nitinol or gold) ribbon to provide self expanding or self closure shape memory element to the anchor tines. Laser cutting can be programming to cut around the embedded ribbon wire to include the wire into the body of the helix.

FIG. 17A-17B illustrate yet another approach by which the anchor 10 may be formed. Helical anchors, such as any of those described herein, can be formed by injection molding using a multi-piece mold design. For example, two, three or four piece mold designs can be used to mold the anchors as a single integral component. In one aspect, the mold can be configured so as to release the anchor at an angle that is specific to the design of the anchors. A shown in FIG. 17A, a three-piece mold 17 is used to form anchor 10 by an injection molding process. A core pin 18 is used along with the mold to form the open lumen of the anchor. FIG. 17B shows a four piece mold design 17′ also configured for use with the core pin 18 to allow formation of an anchor 10 through an injection molding process. One advantage to using an injection molding process to form the anchor, is that molded anchors can have variable thickness along the length of the component. For example, such an anchor can be formed so that the base is thinner to improve crossing profile and the protruding tines are thicker to provide retention strength after implantation. In another aspect, a metallic element can be incorporated along the entire length, at the location of the tines, or in the distal and proximal ends for radiopacity.

Methods of forming anchor in accordance with aspects of the invention described above are shown in the examples of FIG. 18-19. The example method of FIG. 18 includes method steps of: laser cutting a helical pattern into a tubular section of material, the pattern corresponding to an neurostimulation lead anchor having a plurality of tines in a constrained configuration 180; supporting the tines of the tubular section in an outwardly protruding position corresponding to a deployed configuration of the anchor 182; and heat setting the tubular section while the tines are supported thereby setting the material while the anchor is in the deployed configuration 184. In one aspect, the material is Nitinol, preferably in the superelastic phase and having an austenitic finish temperature from about 15 degrees C. to about 35 degrees C., so that the anchor will return to the deployed configuration upon heating in the body. In another aspect, the material may be formed of a polymer material that can be set in the deployed configuration by heating and reflow. The methods may be provided to a user to apply to the lead, or may be affixed to the lead before shipment to the user by wrapping the anchor about an anchoring portion 186. The example method of FIG. 19 includes steps of: assembling a multi-piece mold defining an outer surface of a helical anchor having a plurality of outwardly extending tines with a central core pin defining a central lumen of the anchor 190; injecting the flowable material into the assembled mold and allowing the material to at least partly set 194; and removing the mold to release the anchor 196. In some embodiments, the molds are configured such that the outer pieces of the mold are removed along a direction in which the tines extend, which reduces the stress and forces applied to the tines during removal. In some embodiments, a radiopaque ribbon within the mold during assembly and/or adding a radiopaque material to a flowable material for forming the anchor 192. Again, the anchor may be provided to the user for assembly with the lead or applied to the lead 198 and supplied to the user assembled with the lead. In another aspect, the anchor may be provided with the lead within a constraining sheath ready for insertion into the patient according to the implantation methods described herein.

Methods of affixing an implanted neurostimulation lead using an anchor in accordance with aspects of the invention are show in the examples of FIGS. 20-21. The example method of FIG. 20 includes steps of: providing a neurostimulation lead having one or more neurostimulation electrodes and an anchor proximal the one or more electrodes, the anchor including a helical body wrapped along a length of the lead and one or more of tines attached to the helical body folded inward against the lead body the helical body constrained by a sheath 210; advancing the lead through a tissue of a patient to a target location while the one or more tines are folded inward against the lead body constrained by the sheath 212; resiliently deploying the one or more tines to a deployed configuration extended laterally outward from the helical body by withdrawing the sheath 214; and anchoring the neurostimulation lead at the target location by engaging the one or more tines in the deployed configuration against adjacent tissues thereby inhibiting axial movement of the lead 216. Lead removal may be effected by proximally withdrawing the lead until the anchoring force provided by the flexible tines is overcome. Thus, the tines are fabricated from a material having sufficient stiffness to provide a desired anchoring force but flexible enough to avoid tissue damage when withdrawn.

In the foregoing specification, the invention is described with reference to specific embodiments thereof, but those skilled in the art will recognize that the invention is not limited thereto. Various features and aspects of the above-described invention can be used individually or jointly. Further, the invention can be utilized in any number of environments and applications beyond those described herein without departing from the broader spirit and scope of the specification. The specification and drawings are, accordingly, to be regarded as illustrative rather than restrictive. It will be recognized that the terms “comprising,” “including,” and “having,” as used herein, are specifically intended to be read as open-ended terms of art.

Claims

1. An anchor for anchoring an implanted neurostimulation lead at a tissue location in a body of a patient, the anchor comprising: a helical body extending helically along a longitudinal axis thereof; anda plurality of tines extending from the helical body, wherein each of the plurality of tines is biased toward a deployed configuration and resiliently deflectable for a delivery configuration,wherein the helical body and the plurality of tines are formed from a single integral tube,wherein in the deployed configuration, the plurality of tines extend laterally away from the longitudinal axis of the helical body, and in the delivery configuration, the plurality of tines are folded inward toward the longitudinal axis of the helical body to facilitate delivery of a lead during implantation, andwherein the anchor is molded from a polyurethane based material having a shore hardness in a range between 50A and 80D.
2. The anchor of claim 1, wherein the anchor is configured such that when attached to a lead body in the delivery configuration, each of the plurality of tines is configured to be folded directly against the lead body.
3. The anchor of claim 2, wherein each of the plurality of tines is configured to be folded against the lead body without overlapping a section of the helical body.
4. The anchor of claim 1, wherein the plurality of tines are substantially flush with the helical body of the anchor when in the delivery configuration.
5. The anchor of claim 1, wherein each of the plurality of tines has a rectangular shape.
6. The anchor of claim 1, wherein the anchor is dimensioned such that, when attached to a lead body and in the delivery configuration, the anchor has a cross sectional profile sufficiently small to facilitate delivery through a 5 French sheath.
7. The anchor of claim 1, wherein the helical body and the plurality of tines are integrally formed of a common material.
8. The anchor of claim 1, wherein the anchor is formed of a material with sufficient stiffness so that, when attached to an implanted lead and in the deployed configuration, engagement of tissue with the plurality of tines inhibits axial movement of the implanted lead when implanted in a tissue of the patient at a target location.
9. The anchor of claim 1, wherein, in the deployed configuration, each of the plurality of tines is angled in a proximal direction.
10. An anchor for anchoring an implanted neurostimulation lead at a tissue location in a body of a patient, the anchor comprising: a helical body extending helically along a longitudinal axis thereof; anda plurality of tines extending from the helical body, wherein each of the plurality of tines is biased toward a deployed configuration and resiliently deflectable for a delivery configuration,wherein in the delivery configuration, the plurality of tines are substantially flush with the helical body,wherein in the deployed configuration, the plurality of tines extend laterally away from the longitudinal axis of the helical body, and in the delivery configuration, the plurality of tines are folded inward toward the longitudinal axis of the helical body to facilitate delivery of a lead during implantation, andwherein the anchor is molded from a polyurethane based material having a shore hardness in a range between 50A and 80D.
11. The anchor of claim 10, wherein the anchor is configured such that when attached to a lead body in the delivery configuration, each of the plurality of tines is configured to be folded directly against the lead body.
12. The anchor of claim 11, wherein each of the plurality of tines is configured to be folded against the lead body without overlapping a section of the helical body.
13. The anchor of claim 10, wherein each of the plurality of tines has a rectangular shape.
14. The anchor of claim 10, wherein the anchor is dimensioned such that, when attached to a lead body and in the delivery configuration, the anchor has a cross sectional profile sufficiently small to facilitate delivery through a 5 French sheath.
15. The anchor of claim 10, wherein the helical body and the plurality of tines are integrally formed of a common material.
16. The anchor of claim 10, wherein the anchor is formed of a material with sufficient stiffness so that, when attached to an implanted lead and in the deployed configuration, engagement of tissue with the plurality of tines inhibits axial movement of the implanted lead when implanted in a tissue of the patient at a target location.
17. The anchor of claim 10, wherein, in the deployed configuration, each of the plurality of tines is angled in a proximal direction.
18. The anchor of claim 10, wherein, in the deployed configuration, each of the plurality of tines extend laterally outward from the longitudinal axis at an angle between 30 and 80 degrees from the longitudinal axis.

CROSS-REFERENCES TO RELATED APPLICATIONS

The present application is a divisional of U.S. Non-Provisional application Ser. No. 15/719,487 filed on Sep. 28, 2017, which is a divisional of U.S. Non-Provisional application Ser. No. 14/827,074 filed on Aug. 14, 2015, which claims the benefit of priority of U.S. Provisional Application No. 62/038,122 filed on Aug. 15, 2014 and U.S. Provisional Application No. 62/110,274 filed on Jan. 30, 2015; each of which is incorporated herein by reference in its entirety. The present application is also related to concurrently filed U.S. Non-Provisional patent application Ser. No. 14/827,081, entitled “External Pulse Generator Device and Associated Methods for Trial Nerve Stimulation;” U.S. Non-Provisional patent application Ser. No. 14/827,108, entitled “Electromyographic Lead Positioning and Stimulation Titration in a Nerve Stimulation System for Treatment of Overactive Bladder;” U.S. Non-Provisional patent application Ser. No. 14/827,095, entitled “Integrated Electromyographic Clinician Programmer For Use With an Implantable Neurostimulator;” and U.S. Non-Provisional patent application Ser. No. 14/827,067, entitled “Systems and Methods for Neurostimulation Electrode Configurations Based on Neural Localization;” and U.S. Provisional Application Nos. 62/101,666, entitled “Patient Remote and Associated Methods of Use With a Nerve Stimulation System” filed on Jan. 9, 2015; 62/101,884, entitled “Attachment Devices and Associated Methods of Use With a Nerve Stimulation Charging Device” filed on Jan. 9, 2015; 62/101,782, entitled “Improved Antenna and Methods of Use For an Implantable Nerve Stimulator” filed on Jan. 9, 2015; and 62/191,134, entitled “Implantable Nerve Stimulator Having Internal Electronics Without ASIC and Methods of Use” filed on Jul. 10, 2015; each of which is assigned to the same assignee and incorporated herein by reference in its entirety for all purposes.

US Referenced Citations (594)

Number	Name	Date	Kind
3057356	Greatbatch	Oct 1962	A
3348548	Chardack	Oct 1967	A
3646940	Timm et al.	Mar 1972	A
3824129	Fagan, Jr.	Jul 1974	A
3825015	Berkovits	Jul 1974	A
3888260	Fischell	Jun 1975	A
3902501	Citron et al.	Sep 1975	A
3939843	Smyth	Feb 1976	A
3942535	Schulman	Mar 1976	A
3970912	Hoffman	Jul 1976	A
3995623	Blake et al.	Dec 1976	A
4019518	Maurer et al.	Apr 1977	A
4044774	Corbin et al.	Aug 1977	A
4082097	Mann et al.	Apr 1978	A
4141365	Fischell et al.	Feb 1979	A
4166469	Littleford	Sep 1979	A
4269198	Stokes	May 1981	A
4285347	Hess	Aug 1981	A
4340062	Thompson et al.	Jul 1982	A
4379462	Borkan et al.	Apr 1983	A
4407303	Akerstrom	Oct 1983	A
4437475	White	Mar 1984	A
4512351	Pohndorf	Apr 1985	A
4550731	Batina et al.	Nov 1985	A
4558702	Barreras et al.	Dec 1985	A
4654880	Sontag	Mar 1987	A
4662382	Sluetz et al.	May 1987	A
4719919	Marchosky et al.	Jan 1988	A
4721118	Harris	Jan 1988	A
4722353	Sluetz	Feb 1988	A
4744371	Harris	May 1988	A
4800898	Hess et al.	Jan 1989	A
4848352	Pohndorf et al.	Jul 1989	A
4860446	Lessar et al.	Aug 1989	A
4957118	Erlebacher	Sep 1990	A
4989617	Memberg et al.	Feb 1991	A
5012176	Laforge	Apr 1991	A
5052407	Hauser et al.	Oct 1991	A
5197466	Marchosky et al.	Mar 1993	A
5204611	Nor et al.	Apr 1993	A
5255691	Otten	Oct 1993	A
5257634	Kroll	Nov 1993	A
5342408	Decoriolis et al.	Aug 1994	A
5366493	Scheiner et al.	Nov 1994	A
5439485	Mar et al.	Aug 1995	A
5476499	Hirschberg	Dec 1995	A
5484445	Knuth	Jan 1996	A
5571148	Loeb et al.	Nov 1996	A
5592070	Mino	Jan 1997	A
5637981	Nagai et al.	Jun 1997	A
5676162	Larson, Jr. et al.	Oct 1997	A
5690693	Wang et al.	Nov 1997	A
5702428	Tippey et al.	Dec 1997	A
5702431	Wang et al.	Dec 1997	A
5712795	Layman et al.	Jan 1998	A
5713939	Nedungadi et al.	Feb 1998	A
5733313	Barreras, Sr. et al.	Mar 1998	A
5735887	Barreras, Sr. et al.	Apr 1998	A
5741316	Chen et al.	Apr 1998	A
5871532	Schroeppel	Feb 1999	A
5876423	Braun	Mar 1999	A
5902331	Bonner et al.	May 1999	A
5948006	Mann	Sep 1999	A
5949632	Barreras, Sr. et al.	Sep 1999	A
5957965	Moumane et al.	Sep 1999	A
5991665	Wang et al.	Nov 1999	A
6027456	Feler et al.	Feb 2000	A
6035237	Schulman et al.	Mar 2000	A
6052624	Mann	Apr 2000	A
6055456	Gerber	Apr 2000	A
6057513	Ushikoshi et al.	May 2000	A
6067474	Schulman et al.	May 2000	A
6075339	Reipur et al.	Jun 2000	A
6076017	Taylor et al.	Jun 2000	A
6081097	Seri et al.	Jun 2000	A
6083247	Rutten et al.	Jul 2000	A
6104957	Alo et al.	Aug 2000	A
6104960	Duysens et al.	Aug 2000	A
6138681	Chen et al.	Oct 2000	A
6165180	Cigaina et al.	Dec 2000	A
6166518	Echarri et al.	Dec 2000	A
6169387	Kaib	Jan 2001	B1
6172556	Prentice	Jan 2001	B1
6178353	Griffith et al.	Jan 2001	B1
6181105	Cutolo et al.	Jan 2001	B1
6191365	Avellanet	Feb 2001	B1
6208894	Schulman et al.	Mar 2001	B1
6212430	Kung	Apr 2001	B1
6212431	Hahn et al.	Apr 2001	B1
6221513	Lasater	Apr 2001	B1
6227204	Baumann et al.	May 2001	B1
6243608	Pauly et al.	Jun 2001	B1
6246911	Seligman	Jun 2001	B1
6249703	Stanton et al.	Jun 2001	B1
6265789	Honda et al.	Jul 2001	B1
6275737	Mann	Aug 2001	B1
6278258	Echarri et al.	Aug 2001	B1
6305381	Weijand et al.	Oct 2001	B1
6306100	Prass	Oct 2001	B1
6315721	Schulman et al.	Nov 2001	B2
6316909	Honda et al.	Nov 2001	B1
6321118	Hahn	Nov 2001	B1
6327504	Dolgin et al.	Dec 2001	B1
6354991	Gross et al.	Mar 2002	B1
6360750	Gerber et al.	Mar 2002	B1
6381496	Meadows et al.	Apr 2002	B1
6393325	Mann et al.	May 2002	B1
6438423	Rezai et al.	Aug 2002	B1
6442434	Zarinetchi et al.	Aug 2002	B1
6453198	Torgerson et al.	Sep 2002	B1
6466817	Kaula et al.	Oct 2002	B1
6473652	Sarwal et al.	Oct 2002	B1
6500141	Irion	Dec 2002	B1
6505075	Weiner	Jan 2003	B1
6505077	Kast et al.	Jan 2003	B1
6510347	Borkan	Jan 2003	B2
6516227	Meadows et al.	Feb 2003	B1
6517227	Stidham et al.	Feb 2003	B2
6542846	Miller et al.	Apr 2003	B1
6553263	Meadows et al.	Apr 2003	B1
6584355	Stessman	Jun 2003	B2
6600954	Cohen et al.	Jul 2003	B2
6609031	Law et al.	Aug 2003	B1
6609032	Woods et al.	Aug 2003	B1
6609945	Jimenez et al.	Aug 2003	B2
6652449	Gross et al.	Nov 2003	B1
6662051	Eraker et al.	Dec 2003	B1
6664763	Echarri et al.	Dec 2003	B2
6685638	Taylor et al.	Feb 2004	B1
6721603	Zabara et al.	Apr 2004	B2
6735474	Loeb et al.	May 2004	B1
6745077	Griffith et al.	Jun 2004	B1
6792314	Byers et al.	Sep 2004	B2
6809701	Amundson et al.	Oct 2004	B2
6836684	Rijkhoff et al.	Dec 2004	B1
6847849	Mamo et al.	Jan 2005	B2
6892098	Ayal et al.	May 2005	B2
6895280	Meadows et al.	May 2005	B2
6896651	Gross et al.	May 2005	B2
6901287	Davis et al.	May 2005	B2
6941171	Mann et al.	Sep 2005	B2
6971393	Mamo et al.	Dec 2005	B1
6989200	Byers et al.	Jan 2006	B2
6990376	Tanagho et al.	Jan 2006	B2
6999819	Swoyer et al.	Feb 2006	B2
7051419	Schrom et al.	May 2006	B2
7054689	Whitehurst et al.	May 2006	B1
7069081	Biggs et al.	Jun 2006	B2
7127298	He et al.	Oct 2006	B1
7131996	Wasserman et al.	Nov 2006	B2
7142925	Bhadra et al.	Nov 2006	B1
7146219	Sieracki et al.	Dec 2006	B2
7151914	Brewer	Dec 2006	B2
7167749	Biggs et al.	Jan 2007	B2
7167756	Torgerson et al.	Jan 2007	B1
7177690	Woods et al.	Feb 2007	B2
7177698	Klosterman et al.	Feb 2007	B2
7181286	Sieracki et al.	Feb 2007	B2
7184836	Meadows et al.	Feb 2007	B1
7187978	Malek et al.	Mar 2007	B2
7191005	Stessman	Mar 2007	B2
7212110	Martin et al.	May 2007	B1
7225028	Della Santina et al.	May 2007	B2
7225032	Schmeling et al.	May 2007	B2
7231254	DiLorenzo	Jun 2007	B2
7234853	Givoletti	Jun 2007	B2
7239918	Strother et al.	Jul 2007	B2
7245972	Davis	Jul 2007	B2
7286880	Olson et al.	Oct 2007	B2
7295878	Meadows et al.	Nov 2007	B1
7305268	Gliner et al.	Dec 2007	B2
7317948	King et al.	Jan 2008	B1
7324852	Barolat et al.	Jan 2008	B2
7324853	Ayal et al.	Jan 2008	B2
7328068	Spinelli et al.	Feb 2008	B2
7330764	Swoyer et al.	Feb 2008	B2
7359751	Erickson et al.	Apr 2008	B1
7369894	Gerber	May 2008	B2
7386348	North et al.	Jun 2008	B2
7387603	Gross et al.	Jun 2008	B2
7396265	Darley et al.	Jul 2008	B2
7415308	Gerber et al.	Aug 2008	B2
7444181	Shi et al.	Oct 2008	B2
7444184	Boveja et al.	Oct 2008	B2
7450991	Smith et al.	Nov 2008	B2
7460911	Cosendai et al.	Dec 2008	B2
7463928	Lee et al.	Dec 2008	B2
7470236	Kelleher et al.	Dec 2008	B1
7483752	Von Arx et al.	Jan 2009	B2
7486048	Tsukamoto et al.	Feb 2009	B2
7496404	Meadows et al.	Feb 2009	B2
7515967	Phillips et al.	Apr 2009	B2
7532936	Erickson et al.	May 2009	B2
7539538	Parramon et al.	May 2009	B2
7551960	Forsberg et al.	Jun 2009	B2
7555346	Woods et al.	Jun 2009	B1
7565203	Greenberg et al.	Jul 2009	B2
7578819	Bleich et al.	Aug 2009	B2
7580752	Gerber et al.	Aug 2009	B2
7582053	Gross et al.	Sep 2009	B2
7617002	Goetz	Nov 2009	B2
7640059	Forsberg et al.	Dec 2009	B2
7643880	Tanagho et al.	Jan 2010	B2
7650192	Wahlstrand	Jan 2010	B2
7676275	Farazi et al.	Mar 2010	B1
7706889	Gerber et al.	Apr 2010	B2
7720547	Denker et al.	May 2010	B2
7725191	Greenberg et al.	May 2010	B2
7734355	Cohen et al.	Jun 2010	B2
7738963	Hickman et al.	Jun 2010	B2
7738965	Phillips et al.	Jun 2010	B2
7747330	Nolan et al.	Jun 2010	B2
7771838	He et al.	Aug 2010	B1
7774069	Olson et al.	Aug 2010	B2
7801619	Gerber et al.	Sep 2010	B2
7813803	Heruth et al.	Oct 2010	B2
7813809	Strother et al.	Oct 2010	B2
7826901	Lee et al.	Nov 2010	B2
7848818	Barolat et al.	Dec 2010	B2
7878207	Goetz et al.	Feb 2011	B2
7881783	Bonde et al.	Feb 2011	B2
7904167	Klosterman et al.	Mar 2011	B2
7912555	Swoyer et al.	Mar 2011	B2
7925357	Phillips et al.	Apr 2011	B2
7932696	Peterson	Apr 2011	B2
7933656	Sieracki et al.	Apr 2011	B2
7935051	Miles et al.	May 2011	B2
7937158	Erickson et al.	May 2011	B2
7952349	Huang et al.	May 2011	B2
7957818	Swoyer	Jun 2011	B2
7979119	Kothandaraman et al.	Jul 2011	B2
7979126	Payne et al.	Jul 2011	B2
7988507	Darley et al.	Aug 2011	B2
8000782	Gharib et al.	Aug 2011	B2
8000800	Takeda et al.	Aug 2011	B2
8000805	Swoyer et al.	Aug 2011	B2
8005535	Gharib et al.	Aug 2011	B2
8005549	Boser et al.	Aug 2011	B2
8005550	Boser et al.	Aug 2011	B2
8019423	Possover	Sep 2011	B2
8019443	Schleicher et al.	Sep 2011	B2
8024047	Olson et al.	Sep 2011	B2
8036756	Swoyer et al.	Oct 2011	B2
8044635	Peterson	Oct 2011	B2
8050769	Gharib et al.	Nov 2011	B2
8055337	Moffitt et al.	Nov 2011	B2
8068912	Kaula et al.	Nov 2011	B2
8083663	Gross et al.	Dec 2011	B2
8103360	Foster	Jan 2012	B2
8116862	Stevenson et al.	Feb 2012	B2
8121701	Woods et al.	Feb 2012	B2
8129942	Park et al.	Mar 2012	B2
8131358	Moffitt et al.	Mar 2012	B2
8140168	Olson et al.	Mar 2012	B2
8145324	Stevenson et al.	Mar 2012	B1
8150530	Wesselink	Apr 2012	B2
8175717	Haller et al.	May 2012	B2
8180451	Hickman et al.	May 2012	B2
8180452	Shaquer	May 2012	B2
8180461	Mamo et al.	May 2012	B2
8214042	Ozawa et al.	Jul 2012	B2
8214048	Whitehurst et al.	Jul 2012	B1
8214051	Sieracki et al.	Jul 2012	B2
8219196	Torgerson	Jul 2012	B2
8219202	Giftakis et al.	Jul 2012	B2
8224460	Schleicher et al.	Jul 2012	B2
8233990	Goetz	Jul 2012	B2
8255057	Fang et al.	Aug 2012	B2
8311636	Gerber et al.	Nov 2012	B2
8314594	Scott et al.	Nov 2012	B2
8332040	Winstrom	Dec 2012	B1
8340786	Gross et al.	Dec 2012	B2
8362742	Kallmyer	Jan 2013	B2
8369943	Shuros et al.	Feb 2013	B2
8386048	McClure et al.	Feb 2013	B2
8417346	Giftakis et al.	Apr 2013	B2
8423146	Giftakis et al.	Apr 2013	B2
8447402	Jiang et al.	May 2013	B1
8447408	North et al.	May 2013	B2
8457756	Rahman	Jun 2013	B2
8457758	Olson et al.	Jun 2013	B2
8467875	Bennett et al.	Jun 2013	B2
8480437	Dilmaghanian et al.	Jul 2013	B2
8494625	Hargrove	Jul 2013	B2
8515545	Trier	Aug 2013	B2
8538530	Orinski	Sep 2013	B1
8543223	Sage et al.	Sep 2013	B2
8544322	Minami et al.	Oct 2013	B2
8549015	Barolat	Oct 2013	B2
8554322	Olson et al.	Oct 2013	B2
8555894	Schulman et al.	Oct 2013	B2
8562539	Marino	Oct 2013	B2
8571677	Torgerson et al.	Oct 2013	B2
8577474	Rahman et al.	Nov 2013	B2
8588917	Whitehurst et al.	Nov 2013	B2
8626314	Swoyer et al.	Jan 2014	B2
8644933	Ozawa et al.	Feb 2014	B2
8655451	Klosterman et al.	Feb 2014	B2
8700175	Fell	Apr 2014	B2
8706254	Vamos et al.	Apr 2014	B2
8725262	Olson et al.	May 2014	B2
8725269	Nolan et al.	May 2014	B2
8738141	Smith et al.	May 2014	B2
8738148	Olson et al.	May 2014	B2
8750985	Parramon et al.	Jun 2014	B2
8761897	Kaula et al.	Jun 2014	B2
8768452	Gerber	Jul 2014	B2
8774912	Gerber	Jul 2014	B2
8855767	Faltys et al.	Oct 2014	B2
8918174	Woods et al.	Dec 2014	B2
8954148	Labbe et al.	Feb 2015	B2
8989861	Su et al.	Mar 2015	B2
9044592	Imran et al.	Jun 2015	B2
9050473	Woods et al.	Jun 2015	B2
9089712	Joshi et al.	Jul 2015	B2
9108063	Olson et al.	Aug 2015	B2
9144680	Kaula et al.	Sep 2015	B2
9149635	Denison et al.	Oct 2015	B2
9155885	Wei et al.	Oct 2015	B2
9166321	Smith et al.	Oct 2015	B2
9168374	Su	Oct 2015	B2
9192763	Gerber et al.	Nov 2015	B2
9197173	Denison et al.	Nov 2015	B2
9199075	Westlund	Dec 2015	B1
9205255	Strother et al.	Dec 2015	B2
9209634	Cottrill et al.	Dec 2015	B2
9216294	Bennett et al.	Dec 2015	B2
9227055	Wahlstrand et al.	Jan 2016	B2
9227076	Sharma et al.	Jan 2016	B2
9238135	Goetz et al.	Jan 2016	B2
9240630	Joshi	Jan 2016	B2
9242090	Atalar et al.	Jan 2016	B2
9244898	Vamos et al.	Jan 2016	B2
9248292	Trier et al.	Feb 2016	B2
9259578	Torgerson et al.	Feb 2016	B2
9259582	Joshi et al.	Feb 2016	B2
9265958	Joshi et al.	Feb 2016	B2
9270134	Gaddam et al.	Feb 2016	B2
9272140	Gerber et al.	Mar 2016	B2
9283394	Whitehurst et al.	Mar 2016	B2
9295851	Gordon et al.	Mar 2016	B2
9308022	Chitre et al.	Apr 2016	B2
9308382	Strother et al.	Apr 2016	B2
9314616	Wells et al.	Apr 2016	B2
9320899	Parramon et al.	Apr 2016	B2
9333339	Weiner	May 2016	B2
9352148	Stevenson et al.	May 2016	B2
9352150	Stevenson et al.	May 2016	B2
9358039	Kimmel et al.	Jun 2016	B2
9364658	Wechter	Jun 2016	B2
9375574	Kaula et al.	Jun 2016	B2
9393423	Parramon et al.	Jul 2016	B2
9399137	Parker et al.	Jul 2016	B2
9409020	Parker	Aug 2016	B2
9415211	Bradley et al.	Aug 2016	B2
9427571	Sage et al.	Aug 2016	B2
9427573	Gindele et al.	Aug 2016	B2
9427574	Lee et al.	Aug 2016	B2
9433783	Wei et al.	Sep 2016	B2
9436481	Drew	Sep 2016	B2
9446245	Grill et al.	Sep 2016	B2
9463324	Olson et al.	Oct 2016	B2
9468755	Westlund et al.	Oct 2016	B2
9471753	Kaula et al.	Oct 2016	B2
9480846	Strother et al.	Nov 2016	B2
9492672	Vamos et al.	Nov 2016	B2
9492675	Torgerson et al.	Nov 2016	B2
9492678	Chow	Nov 2016	B2
9498628	Kaemmerer et al.	Nov 2016	B2
9502754	Zhao et al.	Nov 2016	B2
9504830	Kaula et al.	Nov 2016	B2
9522282	Chow et al.	Dec 2016	B2
9592389	Moffitt	Mar 2017	B2
9610449	Kaula et al.	Apr 2017	B2
9615744	Denison et al.	Apr 2017	B2
9623257	Olson et al.	Apr 2017	B2
9636497	Bradley et al.	May 2017	B2
9643004	Gerber	May 2017	B2
9653935	Cong et al.	May 2017	B2
9656074	Simon et al.	May 2017	B2
9656076	Trier et al.	May 2017	B2
9656089	Yip et al.	May 2017	B2
9675809	Chow	Jun 2017	B2
9687649	Thacker	Jun 2017	B2
9707405	Shishilla et al.	Jul 2017	B2
9713706	Gerber	Jul 2017	B2
9717900	Swoyer et al.	Aug 2017	B2
9724526	Strother et al.	Aug 2017	B2
9731116	Chen	Aug 2017	B2
9737704	Wahlstrand et al.	Aug 2017	B2
9744347	Chen et al.	Aug 2017	B2
9750930	Chen	Sep 2017	B2
9757555	Novotny et al.	Sep 2017	B2
9764147	Torgerson	Sep 2017	B2
9767255	Kaula et al.	Sep 2017	B2
9776002	Parker et al.	Oct 2017	B2
9776006	Parker et al.	Oct 2017	B2
9776007	Kaula et al.	Oct 2017	B2
9782596	Vamos et al.	Oct 2017	B2
9802038	Lee et al.	Oct 2017	B2
9814884	Parker et al.	Nov 2017	B2
9821112	Olson et al.	Nov 2017	B2
9827415	Stevenson et al.	Nov 2017	B2
9827424	Kaula et al.	Nov 2017	B2
9833614	Gliner	Dec 2017	B1
9849278	Spinelli et al.	Dec 2017	B2
9855438	Parramon et al.	Jan 2018	B2
9872988	Kaula et al.	Jan 2018	B2
9878165	Wilder et al.	Jan 2018	B2
9878168	Shishilla et al.	Jan 2018	B2
9882420	Cong et al.	Jan 2018	B2
9884198	Parker	Feb 2018	B2
9889292	Gindele et al.	Feb 2018	B2
9889293	Siegel et al.	Feb 2018	B2
9889306	Stevenson et al.	Feb 2018	B2
9895532	Kaula et al.	Feb 2018	B2
9899778	Hanson et al.	Feb 2018	B2
9901284	Olsen et al.	Feb 2018	B2
9901740	Drees et al.	Feb 2018	B2
9907476	Bonde et al.	Mar 2018	B2
9907955	Bakker et al.	Mar 2018	B2
9907957	Woods et al.	Mar 2018	B2
9924904	Cong et al.	Mar 2018	B2
9931513	Kelsch et al.	Apr 2018	B2
9931514	Frysz et al.	Apr 2018	B2
9950171	Johanek et al.	Apr 2018	B2
9974108	Polefko	May 2018	B2
9974949	Thompson et al.	May 2018	B2
9981121	Seifert et al.	May 2018	B2
9981137	Eiger	May 2018	B2
9987493	Torgerson et al.	Jun 2018	B2
9993650	Seitz et al.	Jun 2018	B2
9999765	Stevenson	Jun 2018	B2
10004910	Gadagkar et al.	Jun 2018	B2
10016596	Stevenson et al.	Jul 2018	B2
10027157	Labbe et al.	Jul 2018	B2
10045764	Scott et al.	Aug 2018	B2
10046164	Gerber	Aug 2018	B2
10047782	Sage et al.	Aug 2018	B2
10052490	Kaula et al.	Aug 2018	B2
10065044	Sharma et al.	Sep 2018	B2
10071247	Childs	Sep 2018	B2
10076661	Wei et al.	Sep 2018	B2
10076667	Kaula et al.	Sep 2018	B2
10083261	Kaula et al.	Sep 2018	B2
10086191	Bonde et al.	Oct 2018	B2
10086203	Kaemmerer	Oct 2018	B2
10092747	Sharma et al.	Oct 2018	B2
10092749	Stevenson et al.	Oct 2018	B2
10095837	Corey et al.	Oct 2018	B2
10099051	Stevenson et al.	Oct 2018	B2
10103559	Cottrill et al.	Oct 2018	B2
10109844	Dai et al.	Oct 2018	B2
10118037	Kaula et al.	Nov 2018	B2
10124164	Stevenson et al.	Nov 2018	B2
10124171	Kaula et al.	Nov 2018	B2
10124179	Norton et al.	Nov 2018	B2
10141545	Kraft et al.	Nov 2018	B2
10173062	Parker	Jan 2019	B2
10179241	Walker et al.	Jan 2019	B2
10179244	Lebaron et al.	Jan 2019	B2
10183162	Johnson et al.	Jan 2019	B2
10188857	North et al.	Jan 2019	B2
10195419	Shiroff et al.	Feb 2019	B2
10206710	Kern et al.	Feb 2019	B2
10213229	Chitre et al.	Feb 2019	B2
10220210	Walker et al.	Mar 2019	B2
10226617	Finley et al.	Mar 2019	B2
10226636	Gaddam et al.	Mar 2019	B2
10236709	Decker et al.	Mar 2019	B2
10238863	Gross et al.	Mar 2019	B2
10238877	Kaula et al.	Mar 2019	B2
10244956	Kane	Apr 2019	B2
10245434	Kaula et al.	Apr 2019	B2
10258800	Perryman et al.	Apr 2019	B2
10265532	Carcieri et al.	Apr 2019	B2
10277055	Peterson et al.	Apr 2019	B2
10293168	Bennett et al.	May 2019	B2
10328253	Wells	Jun 2019	B2
10363419	Simon et al.	Jul 2019	B2
10369275	Olson et al.	Aug 2019	B2
10369370	Shishilla et al.	Aug 2019	B2
10376701	Kaula et al.	Aug 2019	B2
10448889	Gerber et al.	Oct 2019	B2
10456574	Chen et al.	Oct 2019	B2
10471262	Perryman et al.	Nov 2019	B2
10478619	Lee et al.	Nov 2019	B2
10485970	Gerber et al.	Nov 2019	B2
10493282	Caparso et al.	Dec 2019	B2
10493287	Yoder et al.	Dec 2019	B2
10561835	Gerber	Feb 2020	B2
20020040185	Atalar et al.	Apr 2002	A1
20020051550	Leysieffer	May 2002	A1
20020051551	Leysieffer et al.	May 2002	A1
20020140399	Echarri et al.	Oct 2002	A1
20020156513	Borkan	Oct 2002	A1
20020177884	Ahn et al.	Nov 2002	A1
20030028231	Partridge et al.	Feb 2003	A1
20030114899	Woods et al.	Jun 2003	A1
20030212440	Boveja	Nov 2003	A1
20040087984	Kupiecki et al.	May 2004	A1
20040098068	Carbunaru et al.	May 2004	A1
20040172115	Miazga et al.	Sep 2004	A1
20040210290	Omar-Pasha	Oct 2004	A1
20040230282	Cates et al.	Nov 2004	A1
20040250820	Forsell	Dec 2004	A1
20040267137	Peszynski et al.	Dec 2004	A1
20050004619	Wahlstrand et al.	Jan 2005	A1
20050004621	Boveja et al.	Jan 2005	A1
20050021108	Klosterman et al.	Jan 2005	A1
20050075693	Toy et al.	Apr 2005	A1
20050075694	Schmeling et al.	Apr 2005	A1
20050075696	Forsberg et al.	Apr 2005	A1
20050075697	Olson et al.	Apr 2005	A1
20050075698	Phillips et al.	Apr 2005	A1
20050075699	Olson et al.	Apr 2005	A1
20050075700	Schommer et al.	Apr 2005	A1
20050104577	Matei et al.	May 2005	A1
20050187590	Boveja et al.	Aug 2005	A1
20060041295	Osypka	Feb 2006	A1
20060074412	Zerfas et al.	Apr 2006	A1
20060095078	Tronnes	May 2006	A1
20060142822	Tulgar	Jun 2006	A1
20060149345	Boggs et al.	Jul 2006	A1
20060200205	Haller	Sep 2006	A1
20060206166	Weiner	Sep 2006	A1
20070032836	Rope et al.	Feb 2007	A1
20070073295	Biedermann	Mar 2007	A1
20070239224	Bennett et al.	Oct 2007	A1
20070255368	Bonde et al.	Nov 2007	A1
20070255369	Bonde et al.	Nov 2007	A1
20070265675	Lund et al.	Nov 2007	A1
20070293914	Woods et al.	Dec 2007	A1
20080065182	Strother et al.	Mar 2008	A1
20080103570	Gerber	May 2008	A1
20080132969	Bennett et al.	Jun 2008	A1
20080154335	Rope et al.	Jun 2008	A1
20080161874	Bennett et al.	Jul 2008	A1
20080183236	Gerber	Jul 2008	A1
20080183257	Imran et al.	Jul 2008	A1
20090012592	Buysman	Jan 2009	A1
20100076254	Jimenez et al.	Mar 2010	A1
20100076534	Mock	Mar 2010	A1
20100100158	Thrope et al.	Apr 2010	A1
20100160997	Johnson et al.	Jun 2010	A1
20100256696	Schleicher et al.	Oct 2010	A1
20110251662	Griswold et al.	Oct 2011	A1
20110257701	Strother et al.	Oct 2011	A1
20110270269	Swoyer et al.	Nov 2011	A1
20110282416	Hamann et al.	Nov 2011	A1
20110301663	Wang et al.	Dec 2011	A1
20110301667	Olson et al.	Dec 2011	A1
20110313427	Gindele et al.	Dec 2011	A1
20120041512	Weiner	Feb 2012	A1
20120046712	Woods et al.	Feb 2012	A1
20120053665	Stolz et al.	Mar 2012	A1
20120095478	Wang et al.	Apr 2012	A1
20120130448	Woods et al.	May 2012	A1
20120179221	Reddy et al.	Jul 2012	A1
20120191169	Rothstein et al.	Jul 2012	A1
20120203320	DiGiore et al.	Aug 2012	A1
20120232563	Williams	Sep 2012	A1
20120276854	Joshi et al.	Nov 2012	A1
20120276856	Joshi et al.	Nov 2012	A1
20120310317	Lund et al.	Dec 2012	A1
20120330354	Kane et al.	Dec 2012	A1
20130004925	Labbe et al.	Jan 2013	A1
20130006330	Wilder et al.	Jan 2013	A1
20130006331	Weisgarber et al.	Jan 2013	A1
20130018447	Ollivier et al.	Jan 2013	A1
20130023724	Allen et al.	Jan 2013	A1
20130131766	Crosby et al.	May 2013	A1
20130150925	Vamos et al.	Jun 2013	A1
20130150936	Takahashi	Jun 2013	A1
20130150939	Burnes et al.	Jun 2013	A1
20130184773	Libbus et al.	Jul 2013	A1
20130197608	Eiger	Aug 2013	A1
20130207863	Joshi	Aug 2013	A1
20130310894	Trier	Nov 2013	A1
20130331909	Gerber	Dec 2013	A1
20140046407	Ben-Ezra	Feb 2014	A1
20140128952	Jang et al.	May 2014	A1
20140222112	Fell	Aug 2014	A1
20140237806	Smith et al.	Aug 2014	A1
20140277270	Parramon et al.	Sep 2014	A1
20150088227	Shishilla et al.	Mar 2015	A1
20150214604	Zhao et al.	Jul 2015	A1
20170197079	Illegems et al.	Jul 2017	A1
20170340878	Wahlstrand et al.	Nov 2017	A1
20180021587	Strother et al.	Jan 2018	A1
20180036477	Olson et al.	Feb 2018	A1
20190269918	Parker	Sep 2019	A1
20190351244	Shishilla et al.	Nov 2019	A1
20190358395	Olson et al.	Nov 2019	A1

Foreign Referenced Citations (47)

Number	Date	Country
520440	Sep 2011	AT
4664800	Nov 2000	AU
5123800	Nov 2000	AU
2371378	Nov 2000	CA
2554676	Sep 2005	CA
2957962	May 2018	CA
101678203	Mar 2010	CN
102065947	May 2011	CN
103702713	Apr 2014	CN
3146182	Jun 1983	DE
0656218	Jun 1995	EP
1205004	May 2002	EP
1680182	Jul 2006	EP
2243509	Oct 2010	EP
1680182	May 2013	EP
2395128	Feb 2013	ES
1098715	Mar 2012	HK
06510209	Nov 1994	JP
2007268293	Oct 2007	JP
4125357	Jul 2008	JP
9820933	May 1998	WO
9918879	Apr 1999	WO
9934870	Jul 1999	WO
9942173	Aug 1999	WO
0027469	May 2000	WO
0056677	Sep 2000	WO
0065682	Nov 2000	WO
0069012	Nov 2000	WO
0183029	Nov 2001	WO
0209808	Feb 2002	WO
03084433	Oct 2003	WO
2004021876	Mar 2004	WO
2004103465	Dec 2004	WO
2005079295	Sep 2005	WO
2005081740	Sep 2005	WO
2006116205	Nov 2006	WO
2007022180	Feb 2007	WO
2008021524	Feb 2008	WO
2008094952	Aug 2008	WO
2008153726	Dec 2008	WO
2009102536	Aug 2009	WO
2009135075	Nov 2009	WO
2010107751	Sep 2010	WO
2011059565	May 2011	WO
2013063798	May 2013	WO
2013070490	May 2013	WO
2013156038	Oct 2013	WO

Non-Patent Literature Citations (59)

Entry
US 9,601,939 B2, 03/2017, Cong et al. (withdrawn)
“Bu-802a: How Does Rising Internal Resistance Affect Performance? Understanding the Importance of Low Conductivity”, BatteryUniversity.com, Available Online at https://batteryuniversity.com/learn/article/rising_internal_resistance, Accessed from Internet on: May 15, 2020, 10 pages.
“DOE Handbook: Primer on Lead-Acid Storage Batteries”, U.S. Dept. of Energy, Available Online at htt12s://www.stan dards.doe.gov/standards- documents/ I 000/1084-bhdbk-1995/@@images/file, Sep. 1995, 54 pages.
“Medical Electrical Equipment—Part 1: General Requirements for Safety”, British Standard, BS EN 60601-1:1990-BS5724-1:1989, Mar. 1979, 200 pages.
“Summary of Safety and Effectiveness”, Medtronic InterStim System for Urinary Control, Apr. 15, 1999, pp. 1-18.
“The Advanced Bionics PRECISION™ Spinal Cord Stimulator System”, Advanced Bionics Corporation, Apr. 27, 2004, pp. 1-18.
“UL Standard for Safety for Medical and Dental Equipment”, UL 544, 4th edition, Dec. 30, 1998, 128 pages.
Barnhart et al., “A Fixed-Rate Rechargeable Cardiac Pacemaker”, APL Technical Digest, Jan.-Feb. 1970, pp. 2-9.
Benditt et al., “A Combined Atrial/Ventricular Lead for Permanent Dual-Chamber Cardiac Pacing Applications”, Chest, vol. 83, No. 6, Jun. 1983, pp. 929-931.
Bosch et al., “Sacral (S3) Segmental Nerve Stimulation as a Treatment for Urge Incontinence in Patients with Detrusor Instability: Results of Chronic Electrical Stimulation Using an Implantable Neural Prosthesis”, The Journal of Urology, vol. 154, No. 2, Aug. 1995, pp. 504-507.
Boyce et al., “Research Related to the Development of an Artificial Electrical Stimulator for the Paralyzed Human Bladder: a Review”, The Journal of Urology, vol. 91, No. 1, Jan. 1964, pp. 41-51.
Bradley et al., “Further Experience With the Radio Transmitter Receiver Unit for the Neurogenic Bladder”, Journal of Neurosurgery, vol. 20, No. 11, Nov. 1963, pp. 953-960.
Broggi et al., “Electrical Stimulation of the Gasserian Ganglion for Facial Pain: Preliminary Results”, Acta Neurochirurgica, vol. 39, 1987, pp. 144-146.
Cameron et al., “Effects of Posture on Stimulation Parameters in Spinal Cord Stimulation”, Neuromodulation, vol. 1, No. 4, Oct. 1998, pp. 177-183.
Chartier-Kastler , “Sacral Neuromodulation for Treating the Symptoms of Overactive Bladder Syndrome and Non-obstructive Urinary Retention:>10years of Clinical Experience”, Journal Compilation, BJU international, vol. 101, 2007, pp. 417-423.
Connelly et al., “Atrial Pacing Leads Following Open Heart Surgery: Active or Passive Fixation?”, Pacing and Clinical Electrophysiology, vol. 20, No. 10, Oct. 1997, pp. 2429-2433.
Fischell , “The Development of Implantable Medical Devices at the Applied Physics Laboratory”, Johns Hopkins APL Technical Digest, vol. 13 No. 1, 1992, pp. 233-243.
Gaunt et al., “Control of Urinary Bladder Function With Devices: Successes and Failures”, Progress in Brain Research, vol. 152, 2006, pp. 1-24.
Ghovanloo et al., “A Small Size Large Voltage Compliance Programmable Current Source for Biomedical Implantable Microstimulators”, Proceedings of the 25th Annual International Conference of the IEEE EMBS, Sep. 17-21, 2003, pp. 1979-1982.
Helland , “Technical Improvements to be Achieved by the Year 2000: Leads and Connector Technology”, Rate Adaptive Cardiac Pacing, Springer Verlag, 1993, pp. 279-292.
Hidefjall , “The Pace of Innovation-Patterns of Innovation in the Cardiac Pacemaker Industry”, Linkoping University Press, 1997, 398 pages.
Ishihara et al., “A Comparative Study of Endocardial Pacemaker Leads”, Cardiovascular Surgery, Nagoya Ekisaikai Hospital, 1st Dept. of Surgery, Nagoya University School of Medicine, 1981, pp. 132-135.
Jonas et al., “Studies on the Feasibility of Urinary Bladder Evacuation by Direct Spinal Cord Stimulation. I. Parameters of Most Effective Stimulation”, Investigative urology, vol. 13, No. 2, 1975, pp. 142-150.
Kakuta et al., “In Vivo Long Lerm Evaluation of Transcutaneous Energy Lransmission for Lotally Implantable Artificial Heart”, ASAIO Journal, Mar.-Apr. 2000, pp. 1-2.
Kesler et al., “Voltage-to-Frequency Converters”, Available Online at: https://www.analog.com/media/cn/training-seminars/tutorials/ML-028.pdf, 7 pages.
Lazorthes et al., “Chronic Stimulation of the Gasserian Ganglion for Treatment of Atypical Facial Neuralgia”, Pacing and Clinical Electrophysiology, vol. 10, Jan.-Feb. 1987, pp. 257-265.
Lewis et al., “Early Clinical Experience with the Rechargeable Cardiac Pacemaker”, The Annals of Thoracic Surgery, vol. 18, No. 5, Nov. 1974, pp. 490-493.
Love et al., “Experimental Lesting of a Permanent Rechargeable Cardiac Pacemaker”, The Annals of Thoracic Surgery, vol. 17, No. 2, Feb. 1, 1974, pp. 152-156.
Love , “Pacemaker Troubleshooting and Follow-up”, Clinical Cardiac Pacing, Defibrillation, and Resynchronization Therapy, Chapter 24, 2007, pp. 1005-1062.
Madigan et al., “Difficulty of Extraction of Chronically Implanted Tined Ventricular Endocardial Leads”, Journal of the American College of Cardiology, vol. 3, No. 3, Mar. 1984, pp. 724-731.
Meglio , “Percutaneously Implantable Chronic Electrode for Radiofrequency Stimulation of the Gasserian Ganglion. A Perspective in the Management of Trigeminal Pain”, Acta Neurochirurgica, vol. 33, 1984, pp. 521-525.
Meyerson , “Alleviation of Atypical Trigeminal Pain by Stimulation of the Gasserian Ganglion via an Implanted Electrode”, Acta Neurochirurgica Supplementum , vol. 30, 1980, pp. 303-309.
Mitamura et al., “Development of Transcutaneous Energy Transmission System”, Available Online at https://www.researchgate.net/publication/312810915 Ch.28, Jan. 1988, pp. 265-270.
Nakamura et al., “Biocompatibility and Practicality Evaluations of Transcutaneous Energy Transmission Unit for the Totally Implantable Artifical Heart System”, Journal of Artificial Organs, vol. 27, No. 2, 1998, pp. 347-351.
Nashold et al., “Electromicturition in Paraplegia. Implantation of a Spinal Neuroprosthesis”, Arch Surg., vol. 104, Feb. 1972, pp. 195-202.
Painter et al., “Implantation of an Endocardial Tined Lead to Prevent Early Dislodgement”, The Journal of Thoracic and Cardiovascular Surgery, vol. 77, No. 2, Feb. 1979, pp. 249-251.
Perez , “Lead-Acid Battery State of Charge vs. Voltage”, Available Online at http://www.rencobattery.com/resources/SOC vs-Voltage.pdf, Aug.-Sep. 1993, 5 pages.
Schaldach et al., “A Long-Lived, Reliable, Rechargeable Cardiac Pacemaker”, Engineering in Medicine, vol. 1: Advances in Pacemaker Technology, 1975, 34 pages.
Scheuer-Leeser et al., “Polyurethane Leads: Facts and Controversy”, PACE, vol. 6, Mar.-Apr. 1983, pp. 454-458.
Smith , “Changing Standards for Medical Equipment”, UL 544 and UL 187 vs. UL 2601 (“Smith”), 2002, 8 pages.
Tanagho et al., “Bladder Pacemaker: Scientific Basis and Clinical Future”, Urology, vol. 20, No. 6, Dec. 1982, pp. 614-619.
Tanagho , “Neuromodulation and Neurostimulation: Overview and Future Potential”, Translational Androl Urol, vol. 1, No. 1, 2012, pp. 44-49.
Torres et al., “Electrostatic Energy-Harvesting and Battery-Charging CMOS System Prototype”, Available Online at http://rincon mora.gatech.edu/12ublicat/jrnls/tcasi09_hrv_sys.pdf, pp. 1-10.
Young , “Electrical Stimulation of the Trigeminal Nerve Root for the Treatment of Chronic Facial Pain”, Journal of Neurosurgery, vol. 83, No. 1, Jul. 1995, pp. 72-78.
U.S. Appl. No. 14/827,081, filed Aug. 14, 2015.
U.S. Appl. No. 14/827,108, filed Aug. 14, 2015.
U.S. Appl. No. 14/991,752, filed Jan. 8, 2016.
U.S. Appl. No. 14/827,095, filed Aug. 14, 2015.
U.S. Appl. No. 14/827,067, filed Aug. 14, 2015.
U.S. Appl. No. 14/991,784, filed Jan. 8, 2016.
U.S. Appl. No. 62/101,888, filed Jan. 9, 2015.
U.S. Appl. No. 62/101,899, filed Jan. 9, 2015.
U.S. Appl. No. 62/041,611, filed Aug. 25, 2014.
U.S. Appl. No. 62/038,131, filed Aug. 15, 2014.
U.S. Appl. No. 62/101,897, filed Jan. 9, 2015.
U.S. Appl. No. 62/101,666, filed Jan. 9, 2015.
U.S. Appl. No. 62/101,884, filed Jan. 9, 2015.
U.S. Appl. No. 62/101,782, filed Jan. 9, 2015.
U.S. Appl. No. 62/191,134, filed Jul. 10, 2015.

Related Publications (1)

	Number	Date	Country
	20200038652 A1	Feb 2020	US

Provisional Applications (2)

	Number	Date	Country
	62110274	Jan 2015	US
	62038122	Aug 2014	US

Divisions (2)

	Number	Date	Country
Parent	15719487	Sep 2017	US
Child	16597470		US
Parent	14827074	Aug 2015	US
Child	15719487		US

Implantable lead affixation structure for nerve stimulation to alleviate bladder dysfunction and other indication

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

CPC

International Classifications

Term Extension

Abstract